

Prevalence, Clinical Manifestations, Treatment, and Clinical Course of Chronic Urticaria in Elderly: A Systematic Review

Kanokvalai Kulthanan¹, Chuda Rujitharanawong¹, Kanyalak Munprom¹,
Suphattra Trakanwittayarak¹, Phumitthep Phumariyapong¹, Suthasanee Prasertsook¹,
Patompong Ungprasert²

¹Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; ²Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, USA

Correspondence: Patompong Ungprasert, Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, USA, Tel +1 216 986 4000, Fax +1 216 986 4953, Email p.ungprasert@gmail.com

Purpose: Data specific to the epidemiology, clinical features, and management of chronic urticaria (CU) in the geriatric population remain limited and not well understood. We aim to systematically review the prevalence, clinical manifestations, treatment, and clinical course of elderly patients with CU.

Patients and methods: Original articles that included data of elderly (aged >60 years) with CU that were published until February 2021 were searched in PubMed, Scopus, and Embase using predefined search terms. Related articles were evaluated according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses recommendations.

Results: Among the included 85 studies and 1,112,066 elderly CU patients, most (57.4%) were women. The prevalence of elderly CU in the general population ranged from 0.2–2.8%, and from 0.7–33.3% among all CU patients. Compared to adult CU, elderly CU patients had a higher percentage of wheal alone (73.9%), and lower rate of positive autologous serum skin test and atopy. Gastrointestinal diseases were the most common comorbidity (71.9%), and there was a high rate of malignancies and autoimmune diseases. Second generation H₁-antihistamines were commonly used, and achievement of complete control was most often reported. Omalizumab was prescribed in 59 refractory patients, and a significant response to treatment was reported in most patients. The treatment of comorbidities also yielded significant improvement in CU.

Conclusion: Elderly CU was found to be different from adult CU in both clinical and laboratory aspects. H₁- antihistamines are effective as first-line therapy with minimal side-effects at licensed doses. Treatment of secondary causes is important since the elderly usually have age-related comorbidities.

Keywords: prevalence, clinical manifestations, treatment, chronic urticaria, elderly, systematic review

Introduction

People are now living longer due to new innovations in both technology and modern medicine.¹ The result has been a doubling of global life expectancy over the past century, and an increase in the aging population worldwide.² The World Health Organization and the United Nations define elderly as age ≥60 years and age ≥65 years, respectively.^{3,4} Thus, elderly-specific medical care has become and will continue to be a top priority of global public health.

Chronic urticaria (CU) is one of the most common pruritic conditions in the older population.^{5,6} CU is characterized by the presence of recurrent wheal, with or without angioedema, occurring at least twice a week for longer than 6 weeks.⁷ CU can be classified into two subtypes: chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU).⁷ The pathogenesis of CU is still unclear, but it is thought to be related to histamine, other mediators, and cytokines that are released from activated mast cells by degranulation.^{7–9} Among all patient with CU, 4.1–5.5% are elderly.^{10–12} Moreover, several systemic and autoimmune diseases have been reported to be associated with CU in the elderly population, including

hypertension, chronic kidney disease, diabetes mellitus, thyroid disease, atopic dermatitis and other allergic diseases, cardiac and cerebral vascular disease, and cancer.^{11,13–20} CU can also affect various aspects of patient quality of personal and social life, including sleep disorders, anxiety and depression, sexual dysfunction, and decreased work performance.^{21–23}

Our current understanding of CU in the elderly is still limited since the number of studies describing the clinical manifestations and responses to treatment of CU in the geriatric population with CU remains comparatively small. The International EAACI/GA² LEN/EuroGuiDerm/APAAACI Guideline for the Definition, Classification, Diagnosis and Management of Urticaria recommends second generation H₁-antihistamine (sgAH₁) as the first-line treatment for CU.⁷ If disease control is inadequate after 2–4 weeks of treatment, increasing the dose up to 4-fold of the standard dose of sgAH₁ is recommended. For antihistamine-refractory patients, omalizumab and cyclosporine (CsA) are the treatments of choice.⁷ However, the use of some antihistamines and other medications to treat older patients with CU can be limited due to several factors. In recalcitrant cases, other differential diagnoses related to underlying medical conditions should be considered. In an effort to bridge this knowledge gap, this systematic review was conducted to investigate the reported epidemiology, clinical features, treatments, and clinical course in elderly CU from all available studies.

Methods

Protocol and Registration

The protocol of this systematic review has been reviewed and approved by the Siriraj Institutional Review Board (SIRB), Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand with SIRB Protocol No. 107/2564 (Exempt), and followed the standard protocol of Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA).²⁴ Studies published until February 2021 were searched in the PubMed, Scopus, and Embase databases. The search terms were “urticaria and elderly”, “urticaria and aging”, and “urticaria and geriatric”.

Eligibility Criteria for Systematic Review

Case reports, case series, randomized controlled trials (RCTs), prospective cohort, retrospective cohort, and other types of studies that reported the epidemiology and clinical manifestation of CU in patients aged equal to or greater than 60 years were included. Due to the relatively limited number of studies of CU in the elderly, we included the studies performed in patients aged equal to or greater than 60 years, case reports and case series, aiming to collect data from available published evidence as much as possible. Treatment data was also extracted, but it was not part of the inclusion criteria (ie, studies that described only epidemiology and clinical manifestation without a description of treatment were eligible). Five investigators (KK, CR, KM, ST, and SP) independently screened all titles and abstracts of all retrieved articles. Potentially eligible articles were reviewed in full-text to determine their final eligibility. That process was also independently conducted by the same five reviewers. Any disagreement was resolved by discussion and consensus among the five reviewers.

Data Extraction

The following data were independently extracted by the same five investigators (KK, CR, KM, ST, and SP): 1) first author's name and the year of publication; 2) number of reported patients; 3) epidemiology; 4) clinical manifestations; 5) laboratory investigations; and 6) treatment and clinical course. Response to treatment was classified into four groups, as follows: i) complete control was defined as free of symptoms on continuation of treatment; ii) marked improvement was defined as symptoms having improved considerably, but that some symptoms were still present during treatment; iii) partial improvement was defined as partial reduction of severity of symptoms during treatment; and iv) no improvement was defined as no improvement of symptoms while on medications.

Statistical Analysis

Descriptive statistics, including mean plus/minus standard deviation and number and percentage, were used to describe demographic data, clinical manifestation, prevalence, laboratory findings, treatment, and clinical course. All data were analyzed using PASW Statistics for Windows (version 18.0; SPSS, Inc., Chicago, IL).

Results

From the three databases that were searched, 17,645 articles were identified (6,079 from PubMed, 5,579 from Scopus, and 5,987 from Embase). Of those, 3,369 duplicate articles were excluded. The remaining 14,276 articles underwent title and abstract review. This process eliminated 14,127 articles that did not meet the inclusion criteria. The remaining 149 articles underwent full-text review. Of those, 85 articles (three randomized controlled trials, 12 prospective cohort studies, 34 retrospective cohort studies, one case control study, 16 cross-sectional studies, eight cases series, and 11 case reports) fulfilled the inclusion criteria and were included for systematic review (Figure 1).

Proportion of the Elderly Among All Patients with CU, and the Prevalence of CU Among the Elderly

As shown in Table 1, the percentage of elderly among all CU patients from a single-center cohort ranged from 0.7% to 18.0%,^{10,12,20,25–28} while the reported percentage in general population ranged from 14.1% to 33.3%.^{19,29–34} Only two studies reported the percentage of elderly among all CSU patients in the general population (15.6% and 31.5%),^{34,35} while the percentage of elderly among CSU patients from single-center studies ranged from 6.7% to 21.7%.^{20,36–42} The percentage of elderly CIndU patients was reported in five studies.^{32,34,43–45} The highest proportion was described in a general population study (16.3%).³² The prevalence of elderly CU in the general population was reported to range from 0.2% to 2.8%.^{29,33,35,46} (Table 2).

Epidemiological Data

Clinical features and demographic data of the elderly with CU are summarized in Table 3. Women accounted for 57.4%, 63.9%, and 57.9% of elderly CU, CSU, and CIndU, respectively. The mean age at presentation among all CU patients was 70.4±6.2 years. Most presented with wheal alone (73.9%), followed by wheal with angioedema (25.9%). Only 0.2% presented with wheal and anaphylaxis. The average duration of disease prior to diagnosis was 1.9±3.6 years. Allergic rhinitis, asthma, and allergic dermatitis were the three most common associated atopic diseases. Cold urticaria, symptomatic dermographism, and cholinergic urticaria were found in 10.9%, 7.3%, and 3.5% of elderly CU patients, respectively.




Figure 1 Flow diagram of the literature review process in this systematic review. Eighty-five articles were suitable for the inclusion criteria and were included in our systemic review. There were three randomized controlled trials, 12 prospective cohorts, 34 retrospective cohorts, one case-control, 16 cross-sectional, eight case series, and 11 case reports.

Table 1 The Reported Prevalence of Chronic Urticaria, Chronic Spontaneous Urticaria, and Chronic Inducible Urticaria in Elderly Patients Relative to All Reported Cases of These Disorders

Study (year)	Study design	Country	Population	Elderly patients among all reported patients N/Total (%)
Chronic urticaria				
Juhlin (1981) ¹²	Retrospective cohort	Sweden	University Hospital	18/330 (5.5)
Greene et al (1985) ²⁴⁴	Prospective cohort	USA	Department of Dermatology Mayo Clinic	9/50 (18.0)
Mekkes et al (1986) ²⁵	Retrospective cohort	Netherland	Dermatology clinic University Hospital	3/109 (2.8)
Barlow et al (1993) ²⁶	Retrospective cohort	UK	Urticaria clinic St John's Dermatology Centre	1/135 (0.7)
Hashiro et al (1994) ²⁷	Cross-sectional	Japan	Outpatient clinic Hospital	5/30 (16.7)
Gaig et al ^a (2004) ²⁹	Cross-sectional	Spain	Spanish population National telephone directory survey	10/30 (33.3)
Chen et al ^b (2012) ¹⁹	Retrospective cohort	Taiwan	Taiwan population National Health Insurance Research Database	3,615/12,720 (28.4)
Krupashankar et al (2012) ²⁸	Prospective cohort	India	University Hospital	5/80 (6.3)
Magen et al (2013) ⁶³	Retrospective cohort	Israel	Allergy consultation Secondary and tertiary care	124/1,319 (9.4)
Ban et al (2014) ¹¹	Retrospective cohort	South Korea	Allergy clinic University Hospital	37/837 (4.4)
Chuamanochan et al (2016) ¹⁰	Retrospective cohort	Thailand	Urticaria clinic University Hospital	67/1,622 (4.1)
Chu ^b (2017) ³⁰	Retrospective cohort	Taiwan	Taiwan population National Health Insurance Research Database	40,816/177,879 (23.0)
Eun et al (2018) ³¹	Prospective cohort	Korea	Korean Population National Health Insurance Service - National Sample Cohort	447/2,980 (15.0)
Seo et al ^c (2019) ³²	Retrospective cohort	Korea	Korean Population Health Insurance Review and Assessment Service database	41,882/174,579 (24.0)
Wertenteil et al ^d (2019) ³³	Cross-sectional	USA	Multihealth system data analytics and research platform	22,900/69,570 (32.9)
Jankowska-Konsur et al ^e (2019) ³⁴	Cross-sectional	Poland	Poland Population Recruitment from multi centers all over the country	154/1,091 (14.1)
Chung et al (2020) ⁷⁴	Retrospective cohort	Korea	Outpatient clinic University Hospital	26/329 (7.9)
Napolitano et al (2021) ⁴⁵	Retrospective cohort	Italy	Dermatology unit University Hospital	153/1,970 (7.8)
Chronic spontaneous urticaria				
Yang et al (2005) ⁴¹	Cross-sectional	Taiwan	Dermatological Clinics University Hospital	5/75 (6.7)
Hiragun et al (2013) ³⁸	Retrospective cohort	Japan	University Hospital	22/117 (18.8)
Magen et al (2013) ⁶³	Retrospective cohort	Israel	Allergy consultation secondary and tertiary care	92/1,051 (8.8)
Vikramkumar et al (2014) ⁴²	Cross-sectional	India	Department of Dermatology	5/48 (10.4)
Lapi et al ^f (2016) ³⁵	Retrospective cohort	Italy	Italian population The Health Search IMS Health Longitudinal Patient Database	4,242/13,479 (31.5)
Curto-Barredo et al (2018) ³⁶	Retrospective cohort	Spain	Urticaria unit Hospital	119/549 (21.7)
Nettis et al (2018) ⁴⁰	Retrospective cohort	Italy	Secondary care centers	32/322 (9.9)

(Continued)

Table 1 (Continued).

Study (year)	Study design	Country	Population	Elderly patients among all reported patients N/Total (%)
Curto-Barredo et al (2019) ³⁷	Retrospective cohort	Spain	Urticaria unit Hospital	99/549 (18.0)
Jankowska-Konsur et al ^e (2019) ³⁴	Cross-sectional	Poland	Poland Population Recruitment from multi centers all over the country	104/667 (15.6)
Jo et al (2019) ³⁹	Retrospective cohort	South Korea	University Hospital	79/970 (8.1)
Chronic inducible urticaria				
Dover et al ^c (1988) ⁴³	Retrospective cohort	England	Dermatology Hospital	1/44 (2.3)
Katsarou-Katsari et al (2008) ⁴⁴	Retrospective cohort	Greece	Skin allergy division Hospital	10/62 (16.1)
Seo et al ^g (2019) ³²	Retrospective cohort	Korea	Korean Population Health Insurance Review and Assessment Service database	3,290/20,191 (16.3)
Jankowska-Konsur et al ^e (2019) ³⁴	Cross-sectional	Poland	Poland Population Recruitment from multi centers all over the country	46/383 (12.0)
Napolitano et al (2021) ⁴⁵	Retrospective cohort	Italy	Dermatology Unit University Hospital	26/451 (5.8)

Notes: ^aGaig et al conducted a population-based study among adults in Spain. Population sample was randomly selected from a national telephone directory. The phone survey was performed with each individual employing the Computer-assisted Telephone Interview technique. ^bThe database from National Health Insurance Research of Taiwan represented approximately 99.9% of Taiwan's population. ^cDover et al reported the prevalence of delayed pressure urticaria in hospital for diseases of the skin and the dermatology institute. ^dElectronic health records data for a demographically heterogeneous population-based sample of >55 million patients. The database is from 27 participating integrated health care organizations, representing over 55 million unique persons (17% of the population across all four census regions of the United States). ^eThis nationwide, multi-center, cross-sectional questionnaire-based study was performed under the auspices of the Polish Dermatological Society. Ten chronic urticaria patients were recruited by each of 102 dermatologists and allergists from different regions of Poland to achieve a good representation of patients from the whole country. ^fThe database from the Health Search IMS Health Longitudinal Patient Database (HSD) contained the computer-based patient records from about 1,000 general practitioners (GPs) throughout Italy. Included in this study were almost 1 million electronic patient records which met standard quality criteria. They were selected on a geographical basis to represent the whole Italian population. ^gThe database from Health Insurance Review and Assessment Service covers 97.0% of the Korean population. Not all types of urticaria were included in the study of Seo et al. The reported subtypes of chronic inducible urticaria were cholinergic urticaria and cold/heat urticaria, as shown in this table. Prevalence of dermatographism was also reported but not included in this current study, as it was not symptomatic dermatographism, which is chronic inducible urticaria subtypes.

Severity of CU was reported in 19 studies, mostly moderate-to-severe disease activity.^{11,20,40,47–62} Urticaria activity score (weekly total score 42) was used in 13 studies, and the average score among all studies was 22.1±12.2.^{20,40,48,53–55,57–63} The other scores used to report severity were Visual Analog Scale (VAS; total score 10),⁵⁴ Urticaria Activity Score (UAS; total score 9),⁵⁰ Urticaria Activity Score (UAS; total score 15),¹¹ Urticaria Severity Score (USS; total score 93),⁵¹ and Treatment Score (TS; total score 5).^{49,53} Twelve CSU studies reported severity using Urticaria Activity Score (UAS; weekly total score 42) with an average score among studies of 26.1±12.2.^{40,53–55,57–60,62} Severity of CIndU was reported in heat urticaria, which showed a temperature threshold of 38°C, and in cold urticaria which showed 22 mm for the wheal and 40 mm for the flare by cold stimulation test.^{52,56}

Elderly CU Patients Suffer from Various Age-Related Comorbidities

The reported comorbidities of study patients are shown in Table 3. Unspecified gastrointestinal (GI) disease was the most commonly reported comorbidity among elderly CU patients (71.9%), with the majority of cases collected from a large national database (Korean Health Insurance Review and Assessment Service: HIRA).⁶⁴ The reported prevalence of coronary and cerebral vascular disease were also high at 36.7%. The prevalence of dyslipidemia, hypertension, obesity, and diabetes mellitus in elderly CU patients was 42.9%, 18.6%, 16.7%, and 12.6%, respectively. Thyroid diseases were reported in 20 studies,^{10,20,37,45,49–51,53,61,62,65–74} and some of them were related to autoimmune disorders. For example, Grave's disease and Hashimoto's disease was reported in 44.4% and 20.8% of aging CU, respectively. Other common comorbidities were

Table 2 The Reported Prevalence of Chronic Urticaria in the Elderly Population

Study (year)	Study design	Country	Population	Reported chronic urticaria among all elderly patients N/Total (%)
Chronic urticaria				
Gaig et al ^a (2004) ²⁹	Cross-sectional	Spain	Spanish population	10/1,047 (1.0)
Lapi et al ^b (2016) ³⁵	Retrospective cohort	Italy	National telephone directory survey Italian population	13,476/488,145 (2.8)
Wertenteil et al ^c (2019) ³³	Cross-sectional study	USA	The Health Search IMS Health Longitudinal Patient Database Multihealth system data analytics and research platform	22,900/9,757,210 (0.2)
Gaber et al (2020) ⁴⁶	Prospective cohort	Egypt	Outpatient clinic University Hospital	2/260 (0.8)

Notes: ^aGaig et al conducted a population-based study among adults in Spain. Population sample was randomly selected from a national telephone directory. The phone survey was performed with each individual employing the Computer-assisted Telephone Interview technique. ^bThe database from the Health Search IMS Health Longitudinal Patient Database (HSD) contained the computer-based patient records from about 1,000 general practitioners (GPs) throughout Italy. Included in this study were almost 1 million electronic patient records which met standard quality criteria. They were selected on a geographical basis to represent the whole Italian population. ^cElectronic health records data for a demographically heterogeneous population-based sample of >55 million patients. The database is from 27 participating integrated health care organizations, representing over 55 million unique persons (17% of the population across all four census regions of the United States).

osteoporosis (42.9%), Raynaud phenomena (33.3%), gout (20.0%), avascular hip necrosis (20.0%), systemic lupus erythematosus (20.0%), and anemia (20.0%). Malignancies were also reported at a high rate. Most malignancies were unspecified but, among those that were specified, GI cancer was the most prevalent (60.0%). Other possible causes or aggravating factors of CU were paronychia (100.0%), stress (27.3%), unspecified drug allergy (9.1%), parasitic infection (4.7%), collagen vascular disease (3.2%), unspecified food allergy (3.0%), insect bite (2.4%), and aspirin intolerance (2.0%).

Laboratory results in Elderly with CU

As shown in Table 3, a positive autologous serum skin test (ASST) was found in 47.5% of elderly CU patients, which was less than in elderly CSU patients (54.9%). A Basophil histamine release test was reported in six studies,^{50,61,75–78} and the result was positive in five of 13 tested patients (38.5%). There were 22 studies that reported the level of total serum IgE, and 16 of those studies reported the IgE value. The average level among those 16 studies was higher than the normal upper limit.^{11,20,37,40,49,50,52,55,57,61,62,76,79–82} The other six studies reported only whether the level was elevated or not. The value was elevated in 42.1% of patients,^{58,69,75,83–85} and this rate was similar to the 43.8% rate reported in elderly CSU. Erythrocyte sedimentation rate (ESR) was increased in 26.8% and 25.4% of elderly CU and CSU, respectively. Positive D-dimer was found in 50.0% of elderly CU patients, and elevated prothrombin fragment was found in 75.0%.⁸⁶ Antinuclear antibody (ANA) was reported in 13 studies^{10,45,51,56,58,63,65,69,79,82,83,85,87} with an average positivity rate of 16.0% among those studies. Anti-FcεRI antibody was reported in one study (66.7% positive).⁷² Abnormal thyroid hormone was common since it was reported in five of 21 studies.^{65,71–73,77} No study reported abnormal free T3, but 13.0% of elderly CU patients had abnormal free T4 hormone, and 18.2% had abnormal thyroid stimulating hormone. Twenty-four studies reported thyroid autoantibodies with a positivity rate of antithyroid peroxidase antibodies of 26.4%, and a positivity rate of antithyroglobulin antibodies of 15.6%.^{10,11,40,50,51,55,56,60,63,65–67,69–73,77,78,82,83,85,88,89}

Treatments for CU

Among the elderly who achieved complete control with the use of AH₁, sgAH₁ was most often used at a regular dose (24 of 34 patients), whereas first generation H₁-antihistamine (fgAH₁) was prescribed at a high dose (2 of 2 patients). Side-effects of antihistamines were reported in one study. A combination of multiple high-dose fgAH₁, which were hydroxyzine (dose: 25–200 mg/day), diphenhydramine (dose: 25–200 mg/day), and doxepin (dose: 25–125 mg/day), showed

Table 3 The Reported Demographic and Clinical Characteristics of Elderly Patients with Chronic Urticaria (CU), and Compared Between the Two Subtypes of CU – Chronic Spontaneous Urticaria and Chronic Inducible Urticaria

Clinical features: N/Total (%)	CU ^a (N=1,112,066)	CSU (N=891)	CIndU (N=1,568)
Gender			
Female	61,170/106,669 (57.4)	276/432 (63.9)	873/1,509 (57.9)
Age at presentation, mean±SD, years	70.4±6.2	71.6±6.7	69.9±3.8
Symptoms			
Wheal alone	305/413 (73.9)	236/312 (75.6)	NA
Wheal with angioedema	107/413 (25.9)	76/312 (24.4)	NA
Wheal with anaphylaxis	1/413 (0.2)	0/312 (0.0)	1/1 (100.0)
Duration of disease prior diagnosis, mean±SD, years	1.9±3.6	1.9±3.7	NA
Personal history of atopy^b			
Allergic rhinitis	44/233 (18.9)	9/100 (9.0)	9/27 (33.3)
Asthma	84,519/982,862 (8.6)	4/101 (4.0)	2/27 (7.4)
Atopic Dermatitis	57,163/985,228 (5.8)	15/162 (9.3)	4/27 (14.8)
Allergic conjunctivitis	2/73 (2.7)	0/7 (0.0)	1/27 (3.7)
Unspecified atopy	18/144 (12.5)	8/105 (7.6)	0/1 (0.0)
Family history of atopy			
Allergic rhinitis	5/74 (6.8)	0/1 (0.0)	0/2 (0.0)
Asthma	2/74 (2.7)	0/1 (0.0)	0/2 (0.0)
Atopic Dermatitis	1/74 (1.4)	0/1 (0.0)	0/2 (0.0)
Types of chronic inducible urticaria			
Cold urticaria	18/165 (10.9)	NA	7/154 (4.6)
Symptomatic dermatographism	25/344 (7.3)	NA	25/344 (7.3)
Cholinergic urticaria	1,468/42,006 (3.5)	NA	3/124 (2.4)
Delayed pressure urticaria	4/126 (3.2)	NA	2/124 (1.6)
Heat urticaria	3/154 (2.0)	NA	2/153 (1.3)
Solar urticaria	2/125 (1.6)	NA	1/124 (0.8)
Aquagenic urticaria	1/153 (0.7)	NA	1/153 (0.7)
Comorbidity^{b,c}			
Gastrointestinal diseases	708,417/985,284 (71.9)	1/5 (20.0)	NA
Coronary and other vascular diseases			
Cardiac/cerebral vascular diseases	72/196 (36.7)	52/169 (30.8)	19/26 (73.1)
Atrial fibrillation	1/5 (20.0)	1/5 (20.0)	NA
Metabolic diseases			
Dyslipidemia	3/7 (42.9)	2/6 (33.3)	1/1 (100.0)
Hypertension	183,473/986,035 (18.6)	103/264 (39.0)	20/27 (74.1)
Obesity	5/30 (16.7)	0/4 (0.0)	5/26 (19.2)
Diabetes Mellitus	34/271 (12.6)	34/271 (12.6)	NA
Unspecified metabolic syndrome	21/67 (31.3)	21/67 (31.3)	NA
Musculoskeletal diseases			
Osteoporosis	3/7 (42.9)	3/7 (42.9)	NA
Gout	1/5 (20.0)	0/4 (0.0)	NA
Avascular hip necrosis	1/5 (20.0)	1/5 (20.0)	NA
Thyroid diseases			
Hyperthyroidism	1/1 (100.0)	NA	NA
Hypothyroidism	5/9 (55.6)	1/5 (20.0)	NA
Grave's disease	4/9 (44.4)	2/6 (33.3)	NA
Hashimoto's thyroid diseases	22/106 (20.8)	21/105 (20.0)	NA
Parathyroid adenoma	1/5 (20.0)	1/5 (20.0)	NA
Unspecified thyroid diseases	28/142 (19.7)	24/116 (20.7)	4/26 (15.4)

(Continued)

Table 3 (Continued).

Clinical features: N/Total (%)	CU ^a (N=1,112,066)	CSU (N=891)	CIndU (N=1,568)
Systemic diseases			
Raynaud phenomena	2/6 (33.3)	0/4 (0.0)	NA
Systemic lupus erythematosus	1/5 (20.0)	1/5 (20.0)	NA
Anemia	1/5 (20.0)	0/4 (0.0)	NA
Unspecified autoimmune diseases	8/70 (11.4)	8/69 (11.6)	0/1 (0.0)
High myopia	1/5 (20.0)	0/4 (0.0)	NA
Genitourinary disorders			
Benign prostate hyperplasia	3/30 (10.0)	3/30 (10.0)	3/26 (11.5)
Chronic kidney diseases	6/96 (6.3)	6/96 (6.3)	NA
Chronic obstructive pulmonary diseases	2/31 (6.5)	1/5 (20.0)	1/26 (3.8)
Psychiatric problems			
Dementia	4/67 (6.0)	4/67 (6.0)	NA
Unspecified psychiatric problems	5/130 (3.9)	2/103 (1.9)	2/26 (7.7)
Dermatologic diseases			
Psoriasis	4/96 (4.2)	4/96 (4.2)	NA
Contact dermatitis	3/96 (3.1)	3/96 (3.1)	NA
Malignancy			
Gastrointestinal cancer	6/10 (60.0)	0/4 (0.0)	NA
Genitourinary cancer	2/6 (33.3)	0/4 (0.0)	NA
Bronchioalveolar cancer	2/6 (33.3)	0/4 (0.0)	NA
Thyroid cancer	2/6 (33.3)	2/6 (33.3)	NA
Malignant melanoma	1/5 (20.0)	0/4 (0.0)	NA
Hematologic malignancy	35/3,625 (1.0)	0/8 (0.0)	NA
Unspecified malignancy	459/3,714 (12.4)	11/99 (11.1)	NA
Possible causes of urticaria			
Stress	27/99 (27.3)	27/99 (27.3)	NA
Aspirin intolerance	8/42 (2.0)	1/5 (20.0)	0/4 (0.0)
Parasitic infection	6/129 (4.7)	0/4 (0.0)	NA
Collagen vascular disease	4/124 (3.2)	NA	NA
Insect bite	3/126 (2.4)	1/1 (100.0)	1/27 (3.7)
Paronychia	1/1 (100.0)	NA	NA
Unspecified drug allergy	12/132 (9.1)	1/8 (12.5)	NA
Unspecified food allergy	1/33 (3.0)	0/7 (0.0)	1/26 (3.9)
Laboratory investigations			
Positive ASST	125/263 (47.5)	107/195 (54.9)	1/3 (33.3)
Positive SPT	1/9 (11.1)	0/4 (0.0)	1/1 (100.0)
Positive Basophil histamine release test	5/13 (38.5)	4/9 (44.4)	NA
Leukocytosis	4/82 (4.9)	4/70 (5.7)	0/1 (0.0)
Positive HBsAg	8/75 (10.7)	8/68 (11.8)	0/1 (0.0)
Positive anti-HCV	0/70 (0.0)	0/68 (0.0)	0/2 (0.0)
Total serum IgE			
Elevated IgE	8/19 (42.1)	7/16 (43.8)	1/1 (100.0)
IgE level, mean±SD, kU/L			
ImmunoCAP method (normal range 0–119 kU/L) ^d	477.3±288.8	477.3±288.8	NA
Pharmacia CAP System IgE FEIA method ^e (normal range 0–100 kU/L)	164.9±210.4	194.5±269.7	NA
Nephelometry method ^f (normal range 0–100 kU/L)	125	125	NA
Elevated erythrocyte sedimentation rate	22/82 (26.8)	18/71 (25.4)	0/1 (0.0)
Elevated D-dimer	2/4 (50.0)	NA	NA
Elevated prothrombin fragment	3/4 (75.0)	NA	NA

(Continued)

Table 3 (Continued).

Clinical features: N/Total (%)	CU ^a (N=1,112,066)	CSU (N=891)	CIndU (N=1,568)
Abnormal C3	0/18 (0.0)	0/7 (0.0)	0/1 (0.0)
Abnormal C4	2/18 (11.1)	0/7 (0.0)	0/1 (0.0)
Abnormal CH50	1/11 (0.0)	0/5 (0.0)	NA
Abnormal CI-INH	0/13 (0.0)	0/7 (0.0)	NA
Positive antinuclear antibodies	13/81 (16.0)	13/69 (18.8)	0/2 (0.0)
Positive anticentromere antibodies	2/2 (100.0)	NA	NA
Positive Anti-FcεRI antibodies	2/3 (66.7)	2/3 (66.7)	NA
Abnormal free T3	0/22 (0.0)	0/9 (0.0)	0/1 (0.0)
Abnormal free T4	4/31 (12.9)	3/20 (15.0)	0/1 (0.0)
Abnormal TSH	6/33 (18.2)	3/19 (15.8)	0/2 (0.0)
Positive antithyroid peroxidase antibodies	40/150 (26.7)	25/110 (22.7)	1/2 (50.0)
Positive antithyroglobulin antibodies	42/124 (33.9)	31/86 (36.1)	0/1 (0.0)
Abnormal urinalysis	10/64 (15.6)	10/63 (15.9)	NA
Abnormal stool examination	6/85 (7.1)	4/77 (5.2)	NA

Notes: ^aIt should be noted that the CU group included all CU patients aged above 60 years. Studies that reported specifically for CSU or CIndU subtypes were also included in the subgroups of CSU and CIndU. ^bOne patient could have more than one personal history of atopy or one comorbidity. Comorbidity and history of atopy were only showed information from papers which mentioned about each disease. ^cIt should be noted that the studies of Urbach, Lindelof et al, and Chen et al reported only the number of patients with malignancy, other comorbidities were not identified. ^dTotal IgE level measured by ImmunoCAP method were reported in three studies, Ban et al (n=37), Romano et al (n=1), and Nettis et al (n=32), which reported about CU, CSU, and CSU, respectively. Referring to the National Center for Health Statistics, Centers for Disease Control and Prevention, the normal range of total IgE based on ImmunoCAP method is 0–119 kU/L. ^eTotal IgE level measured by Pharmacia CAP method was reported in only one study, Staubach et al (n=4), which reported about CSU. ^fTotal IgE level measured by Nephelometry method was reported in only one study, Kulthanan et al (n=1), which reported about CSU.

Abbreviations: Anti-FcεRI, anti-FcεpsilonRI; ASST, autologous serum skin test; C3, complement C3; C4, complement C4; CH50, total hemolytic complement; CI-INH, complement I esterase inhibitor; CIndU, chronic inducible urticaria; CSU, chronic spontaneous urticaria; CU, chronic urticaria; HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus; Ig, immunoglobulin; NA, not available/not applicable; SD, standard deviation; SPT, skin prick test; TSH, thyroid stimulating hormone.

no additional benefit and caused severe sedation. Treatment in those cases was later changed to omalizumab.⁶⁰ Omalizumab was prescribed in 15 studies. Complete control was observed in 59 of 89 patients, and the prescribed dose ranged from 150 to 300 mg every 2–4 weeks. Fifty patients from five studies received omalizumab alone.^{48,76,81,90,91} Others received omalizumab in combination with other treatments, including with H₁-antihistamine (AH₁) in seven patients from five studies,^{49,50,57,58,61} and systemic corticosteroid in two patients from one study.^{55,60} Side-effects of omalizumab were reported in three studies.^{62,81,90} Two patients experienced nausea, two patients reported asthenia that spontaneously resolved within 48 hours, and one patient had pain at the injection site.

Treatment of Secondary Causes Should Be Considered a Strategy for Controlling CU

Treatment of secondary causes was also effective for controlling CU in the elderly. Thirty-nine studies described the treatment of secondary causes and the outcomes of treatment (Figure 2 and Table 4). More specifically, the following treatments, prescriptions, or procedures improved CU symptoms in the elderly: treatment for *Helicobacter pylori* (*H. pylori*) infection,⁶³ treatment for *Strongyloides* infection,⁹² treatment for thyroid diseases,^{73,88} prescription of immunosuppressants for malignancies,^{79,83,93} prescription of intravenous immunoglobulin (IVIG)^{53,54,60} or sulfasalazine to treat recalcitrant CSU,⁹⁴ and surgical removal of adenoma/neoplasms.^{69,84,85,89,95–97}

Follow-Up Time, Tapering, Relapse, and Mean Duration of Treatment

The follow-up time after completion of treatment was mentioned in 16 studies,^{51,53,54,58,62,69,73,82–85,88,89,92,94,95} and the average follow-up time was 17.5 months. Some patients who had already achieved complete control continued their previous medication during the follow-up period, such as sulfasalazine and sgAH₁, until they could be tapered off.⁹⁴ Methotrexate (MTX) was tapered off in two patients, but one of them relapsed.⁸³ Four patients continued to receive omalizumab maintenance at the same dose with an attempt to increase the interval between doses.^{55,60,91} One patient was prescribed fgAH₁ as needed, but there was no report of the actual frequency of use.⁸⁸ Another patient continued




Figure 2 Treatments and responses to treatment among elderly with chronic urticaria.

Notes: Some patients received more than one type of treatment.

Abbreviations: AH₁, H₁-antihistamine; fgAH₁, first generation H₁-antihistamine; IVIG, intravenous immunoglobulin; LTRA, leukotriene receptor antagonist; MTX, methotrexate; NA, not available/not applicable; sgAH₁, second generation H₁-antihistamine.

levothyroxine for 2 years before tapering, but relapse occurred. The dose was increased back to the initial dose and complete control was re-established.⁵¹ The average duration of treatment in this study was 205.8 days (6.9 months).

Discussion

The results of this systematic review revealed some similarities and differences between adult CU and elderly CU. Previously reported prevalence of CU in adult population ranges from 0.1% to 3.4%, which is relatively similar to the 0.2% to 2.8% prevalence of CU in the elderly.^{33,98} Our review also showed variation between prevalence in various geographic areas. As shown in Table 1, large population and nationwide studies showed a relatively higher prevalence of elderly in the CU population than smaller studies. However, larger studies and smaller studies reported a similar prevalence of CU in the overall elderly population (Table 2).

Even if women formed the majority of this study, which was similar to previous elderly and adult CU reports,^{10,11,23,99,100} some clinical presentations of elderly patients differed from adult CU. Comparison of the reported demographic and clinical characteristics of elderly patients with CU and those of non-elderly is shown in Table 5. Although the majority of both groups presented with wheal alone, its proportions in the elderly were higher than in adults, ranging from 33% to 87% across the studies, while the prevalence of concurrent angioedema was less.^{9,10,12,20,37,40,90} Wheal with anaphylaxis in our review was found only in one case report of the elderly with cold urticaria, which was the type that could have concurrent anaphylaxis up to 3.7–38.0%.^{44,101–107} CSU was the most common subtype among the elderly, similar to adult CU.^{10,20,26,45,108–111} Concerning CIndU, symptomatic dermographism (SD) was reported as the most common CIndU in both groups.^{10,20,45,74,108,112} Similar to the report of Ban et al,¹¹ history of atopy, which is known to be associated with CU, was found at a relatively lower rate in this study than adult CU,^{10,11,20,37,45,64,74,90} in contrast with some previous studies.^{10,11,18} Regarding comorbidities, Lapi et al³⁵ reported the risk of developing CU to be related to numerous factors. Gastrointestinal diseases, being the most common concomitant disease, together with coronary heart diseases, cerebrovascular diseases, metabolic syndrome, autoimmune diseases, thyroid diseases, psychological problems, and malignancies, were all reported at high rates in elderly CU. These findings were consistent with previous studies that reported CU to be associated with increased risk of having metabolic syndrome in both adults and the elderly.^{20,113–115} Moreover, the risk of developing metabolic syndrome was also found to increase with age.^{116,117} As reported by Zbiciak-Nylec et al¹¹⁸ that later onset of urticaria symptoms can result from obesity. Similar to previous studies, autoimmune diseases including autoimmune thyroid diseases, rheumatoid arthritis, and systemic lupus erythematosus had been reported in high rates in all age groups of CU patients, but much more in the elderly.^{17,70,90,119–123} This can be a result from increasing production of autoantibodies with aging, as Ramos-Casals et al¹²⁴ proposed. In addition, a previous nationwide study reported

Table 4 The Reported Treatment for and Clinical Course of Chronic Urticaria in the Elderly

Study (year)	N = Elderly CU/ Total	Treatment									Duration of treatment	Treatment response	Follow-up after treatment and outcome	Side-effects after treatment
		AH _I			Corticosteroids		LTRA	Omalizumab	Immunosuppressant	Others				
		fgAH _I	sgAH _I	Unspecified AH _I	Systemic	Topical								
Prospective Cohort Studies														
Leznoff et al (1983) ⁶⁷	N = 1 of 17	NA	NA	NA	NA	NA	NA	NA	NA	- Levothyroxine (dose: 0.2 mg/d) for euthyroid patient who had autoimmune thyroiditis	NA	Partial improvement	NA	NA
Rumbyrt et al (1995) ⁸⁸	N = 1 of 7	NA	NA	NA	Previous use of - Prednisolone (dose: NA) with no improvement	NA	NA	NA	NA	Previous use of - Famotidine (dose: NA) with no improvement - Doxepin (dose: NA) with no improvement -Thyroxine (0.05 mg/d) for euthyroid patient who had autoimmune thyroiditis	At least 4 weeks	Complete control then discontinued thyroxine	Longer than 1 year of rare hive, with use of Hydroxyzine (dose: NA, as needed)	NA
O'Donnell et al (1998) ⁵⁴	N = 1 of 10	NA	- Cetirizine (dose: 10 mg twice daily)	Previous use of 0 (dose: NA) with no improvement	NA	NA	NA	NA	No	- IVIG (dose: 0.4 g/kg/d for 5 days)	5 days	Partial improvement	6 months	Headache

(Continued)

Table 4 (Continued).

Study (year)	N = Elderly CU/ Total	Treatment									Duration of treatment	Treatment response	Follow-up after treatment and outcome	Side-effects after treatment
		AH _I			Corticosteroids		LTRA	Omalizumab	Immunosuppressant	Others				
		fgAH _I	sgAH _I	Unspecified AH _I	Systemic	Topical								
Sanada et al (2005) ²⁴²	N = 5 of 25	NA	Previous use of - Ebastine (dose: 20 mg/d) with no improvement - Ebastine (dose: 20 mg/d)	NA	NA	NA	- All cases: Montelukast (dose: 10 mg/d)	NA	NA	NA	NA	Complete control	NA	NA
		NA	Previous use of - Ebastine (dose: 20 mg/d) with no improvement - Ebastine (dose: 20 mg/d)		Previous use of - Betamethasone (dose: 0.5 mg/d orally) with no improvement NA							Marked improvement		
		Previous use of - Hydroxyzine (dose: 50 mg/d) with no improvement	Previous use of - Homochlorcyclizine (dose: 30 mg/d) with no improvement - Homochlorcyclizine (dose: 30 mg/d)		NA							No improvement		
		NA	Previous use of - Olopatadine (dose: 20 mg/d) with no improvement - Olopatadine (dose: 20 mg/d)		Previous use of - Betamethasone (dose: 0.5 mg/d orally) with no improvement NA							No improvement		
		NA	Previous use of - Loratadine (dose: 10 mg/d) - Ebastine (dose: 10 mg/d) with no improvement - Loratadine (dose: 10 mg/d) - Ebastine (dose: 10 mg/d)									No improvement		

Kaplan et al ^a (2008) ⁵⁰	N = 2 of 12	- Hydroxyzine (dose: 25–50 mg every 6 hours as needed, total 100– 175 mg/d) - Hydroxyzine (dose: 25–50 mg every 6 hours as needed, total 175 mg/d in the first 4 week then tapered dose until stop at week 8)	NA	NA	NA	NA	NA	- All cases: Omalizumab 150 mg sc every 2 weeks or every 4 weeks	No	NA	4 months	No improvement Complete control	NA	NA
Uysal et al (2014) ⁶¹	N = 3 of 27	NA	All cases: - Desloratadine or fexofenadine; (dose: recommended dose for 3–4 times)	NA	NA	NA	NA	- Omalizumab 150 mg sc every 2 weeks then extend to 5 weeks - Omalizumab 150 mg sc every 2 weeks then extend to 7 weeks - Omalizumab 150 mg sc every 2 weeks then extend to 7 weeks	Previous use of - MTX (dose: NA) with no improvement Previous use of - AZA (dose: NA) with no improvement Previous use of - AZA (dose: NA) with no improvement	NA	112 days 78 days 62 days	Complete control then discontinued omalizumab	NA	NA
Retrospective cohort studies														
McGirt et al (2006) ⁹⁴	N = 2 of 19	Previous use of - Hydroxyzine (dose: maximum 25 mg nightly) with no improvement	Previous use of - Cetirizine (dose: maximum 10 mg/d) with no improvement	NA	Previous use of - Prednisolone (dose: 10 mg/d for 3 days; 2–3 times) with no improvement - Prednisolone (dose: 10 mg/d once for 5 months)	NA	NA	NA	NA	- Sulfasalazine (dose: start at 500 mg/d then increased by 500 mg each week until 2 g/d) for total 12 months	12 months	Complete control then tapered off of sulfasalazine, sgAH ₁	3 months	NA
		NA	Previous use of - Cetirizine (dose: 10 mg/d) with no improvement		Previous use of - Prednisolone dose pack (dose: NA) for 5 courses with no improvement						11 months	Complete control then discontinued sulfasalazine	NA	

(Continued)

Table 4 (Continued).

Study (year)	N = Elderly CU/ Total	Treatment									Duration of treatment	Treatment response	Follow-up after treatment and outcome	Side-effects after treatment
		AH _I			Corticosteroids		LTRA	Omalizumab	Immunosuppressant	Others				
		fgAH _I	sgAH _I	Unspecified AH _I	Systemic	Topical								
Perez et al (2010) ²⁴¹	N = 1 of 16	NA	Previous use of - sgAH _I (unmentioned name, dose: above the recommended dose) with no improvement	NA	Previous use of - Prednisolone (dose: 20 mg/d) with no improvement	NA	NA	NA	Previous use of - CsA (dose: NA) with no improvement - MTX (dose: 5 mg weekly)	Previous use of 0 (unmentioned name, dose: NA) with no improvement - Folic acid (dose: 5 mg weekly)	NA	Marked improvement	NA	NA
Mitzel-Kaoukhov et al (2010) ⁵³	N = 2 of 6	NA	Previous use of - sgAH _I (unmentioned name, dose: 4-fold of the recommended dose) with no improvement	NA	NA	NA	All cases: previous use of - LTRA (unmentioned name, dose: NA) with no improvement	NA	All cases: previous use of - CsA (dose: NA) with no improvement	Previous use of - Histaglobin (dose: NA) with no improvement - IVIG (dose: 2 mg/kg every 4 weeks) for 11 cycles	10 months	Complete control then discontinued	14 months	No
			Previous use of - sgAH _I (unmentioned name, dose: 8-fold of the recommended dose) with no improvement		Previous use of - Systemic corticosteroid (unmentioned name, dose: high dose) with no improvement				NA	Previous use of - Dapsone (dose: NA) with no improvement - IVIG (dose: 2 mg/kg every 4 weeks) for 4 cycles then remission but 4 months later	11 months	Complete control then discontinued	2 months then relapse occurred so IVIG was reinitiated for other 5 cycles	Impairment of pre-existing HT, disappeared after extending the treatment period of IVIG from 2 to 3 days

Sagi et al (2011) ⁸³	N = 5 of 8	All cases: previous use of - fgAH _I (unmentioned name, high dose) with no improvement	All cases: previous use of - sgAH _I (unmentioned name, high dose) with no improvement	NA	Previous use of - Systemic corticosteroid (unmentioned name, dose: NA) with no improvement - Systemic corticosteroid (dose: 30–40 mg/d) for multiple courses then tapered down (dose: NA) - Systemic corticosteroid (dose: 30–40 mg/d) for multiple courses then tapered down (dose: NA) - Systemic corticosteroid (dose: 30–40 mg/d) for multiple courses then tapered down (dose: NA) - Systemic corticosteroid (dose: 30–40 mg/d) for multiple courses then tapered down until off	NA	NA	NA	- MTX (dose: 15 mg weekly) for 1 month then tapering down to 10 and 5 mg oral weekly for 1 and 1 month, respectively)	- Folic acid (dose: 5 mg weekly)	3 months	Complete control then discontinued MTX and folic acid	8 months	No
									5 months		Complete control (still in the MTX tapering process)	NA	Elevated liver enzyme (Twice the normal values) – resolved after reducing MTX dosage	
									3 months		Complete control then discontinued MTX and folic acid	2 months	No	
									2 months		No improvement then discontinued MTX and folic acid due to poor compliance	2 months	Fatigue	
									5 months		Complete control then tapering MTX down but relapse occurred and required a constant dose of MTX 15 mg/ week	NA	Gastrointestinal discomfort – resolved after changing to MTX IM route	
Magen et al (2013) ²⁰	N = 49 of 92	- fgAH _I (unmentioned name; dose: NA) in 8 of 46 patients	- sgAH _I (unmentioned name; dose: NA) in 49 of 49 patients	NA	- Systemic corticosteroid (unmentioned name, dose: NA) in 2 of 49 patients	NA	NA	NA	NA	NA	12 months	Complete control in 34 of 46 patients	NA	NA
Magen et al (2013) ⁶³	N = 1 of 9	NA	NA	NA	NA	NA	NA	NA	- Amoxicillin (dose: 2 g/d) - Clarithromycin (dose: 1 g/d) - Omeprazole (dose: 40 mg/d) for treatment of <i>H. pylori</i> infection	- Amoxicillin (dose: 2 g/d) - Clarithromycin (dose: 1 g/d) - Omeprazole (dose: 40 mg/d) for treatment of <i>H. pylori</i> infection	2 weeks	Complete control then discontinued <i>H. pylori</i> infection treatment	NA	NA

(Continued)

Table 4 (Continued).

Study (year)	N = Elderly CU/ Total	Treatment									Duration of treatment	Treatment response	Follow-up after treatment and outcome	Side-effects after treatment
		AH _I			Corticosteroids		LTRA	Omalizumab	Immunosuppressant	Others				
		fgAH _I	sgAH _I	Unspecified AH _I	Systemic	Topical								
Song et al (2013) ⁵⁵	N = 4 of 16	NA	All cases: previous use of - Cetirizine (dose: 60–80 mg/d) with no improvement	NA	Previous use of - Prednisolone (dose: 15 mg/d) for 10 courses with no improvement - Prednisolone (dose: NA) for short courses Previous use of - Prednisolone (dose: 10 mg/d) for >20 courses with no improvement - Prednisolone (dose: NA) Previous use of - Prednisolone (dose: 5–20 mg/d) for >20 courses with no improvement - Prednisolone (dose: NA) tapered dose then off shortly after start omalizumab Previous use of - Prednisolone (dose: 5–10 mg/d) for >20 courses with no improvement - Prednisolone (dose: NA) tapered dose then off shortly after start omalizumab	NA	NA	All cases: - Omalizumab 150 mg sc every 4 weeks	NA	NA	24 months	Complete control and continued with omalizumab 150 mg sc every 4–8 weeks	NA	No
											2 months	No improvement then discontinued omalizumab and went into spontaneous remission then discontinued prednisolone		Flare of urticaria after first dose of omalizumab injection
											2 months	No improvement then discontinued omalizumab		No
											24 months	Complete control and continued with omalizumab 150 mg sc every 4–8 weeks		No

Romano et al (2015) ⁶²	N= 1 of 9	Previous use of - Cinnarizine (dose: NA) with no improvement	NA	Previous use of -AH ₁ (unmentioned name, dose: NA) with no improvement	Previous use of - Systemic steroid (unmentioned name, dose: NA) with no improvement	NA	Previous use of - LTRA (unmentioned name, dose: NA) with no improvement	- Omalizumab 150 mg sc every 4 weeks	Previous use of - CsA (dose: NA) with no improvement	NA	5 months	No improvement then discontinued omalizumab	42 months	Pain at injected site
Sugiyama et al (2015) ⁷³	N = 2 of 40	NA	Previous use of - Olopatadine (dose: 5 mg/d) with partial improvement - Olopatadine (dose: 5 mg/d) NA	NA	NA	NA	NA	NA	NA	All cases: - Triiodothyronine (dose: 25 g/d) for Hashimoto's disease	3 months	Complete control then discontinued triiodothyronine	>10 months of complete control then recurrence occurred after triggered by upper respiratory tract infection; symptom was well-controlled with olopatadine 2.5 mg/d	NA
Kulthanan et al (2017) ⁵⁷	N = 1 of 13	NA	Previous use of - Desloratadine (dose: 20 mg/d) - Levocetirizine (10 mg/d) with no improvement - Desloratadine (dose: 5–10 mg/d)	NA	Previous use of - Prednisolone (5–10 mg/d) with no improvement	NA	Previous use of - Montelukast (dose: NA) with no improvement	- Omalizumab 150 mg sc every 4 weeks	Previous use of - CsA (dose: NA) - HCQ (dose: NA) with no improvement	Previous use of 0 (unmentioned name, dose: NA) with no improvement	4 months	Complete control then discontinued omalizumab	NA	No
Napolitano et al (2018) ⁹³	N = 1 of 1,493	NA	NA	Previous use of 0 (dose: 4 times of licensed dose) with no improvement	Previous use of - Prednisolone (dose: NA) with partial improvement	NA	NA	NA	NA	- Chemotherapy for small cell lung cancer	NA	Complete control	NA	NA

(Continued)

Table 4 (Continued).

Study (year)	N = Elderly CU/ Total	Treatment									Duration of treatment	Treatment response	Follow-up after treatment and outcome	Side-effects after treatment
		AH _I			Corticosteroids		LT _{RA}	Omalizumab	Immunosuppressant	Others				
		fgAH _I	sgAH _I	Unspecified AH _I	Systemic	Topical								
Napolitano et al (2021) ⁴⁵	N = 26 of 451	NA	- sgAH _I (unmentioned name, recommended dose) in 23 of 26 patients - sgAH _I (unmentioned name, double dose) in 3 of 26 patients with SD	NA	NA	NA	NA	NA	NA	NA	NA	Complete control in 26 of 26 patients	NA	No
Martina et al (2021) ⁹⁰	N = 62 of 62	NA	NA	NA	NA	NA	NA	- Omalizumab 300 mg sc every 4 weeks	NA	NA	3 months	- Complete control in 44 of 62 patients - Partial improvement in 11 of 62 patients - No improvement in 7 of 62 patients	NA	asthenia; spontaneously resolved within 48 hours (2 patients)
Case Series														
Manganoni et al (2007) ⁸⁹	N = 1 of 4	Previous use of - Oxatamide (dose: 60 mg/d) with no improvement	NA	NA	Previous use of - Betamethasone (dose: 2 mg/d orally) with no improvement	NA	NA	NA	NA	- Surgery: total thyroidectomy for papillary thyroid carcinoma	NA	Complete control	60 months	NA
Godse (2011) ⁴⁸	N = 1 of 5	NA	Previous use of - sgAH _I (unmentioned name, dose: 4 times of recommended dose) with no improvement	NA	Previous use of - Systemic corticosteroid (dose: NA) with no improvement	NA	NA	- Omalizumab 300 mg sc every 4 weeks	NA	NA	4 months	Complete control then discontinued omalizumab	NA	NA
Groffik et al (2011) ⁴⁹	N = 1 of 9	NA	Previous use of - sgAH _I (unmentioned name, dose: 4 times of recommended dose) with no improvement	NA	Previous use of - Systemic corticosteroid (dose: NA) for long-term with no improvement	NA	NA	- Omalizumab 300 mg sc every 2 weeks	NA	NA	2 months	Complete control then discontinued omalizumab	NA	NA

Metz et al (2011) ⁵²	N = 1 of 7	NA	Previous use of - Loratadine (recommended dose) - Cetirizine (recommended dose) - Desloratadine (2–6 fold of recommended dose) - Ebastine (recommended dose) - Rupatadine (2–6 fold of recommended dose) - Levocetirizine (recommended dose) with no improvement	NA	NA	NA	Previous use of - Montelukast (dose: NA)	- Omalizumab 300 mg sc every 2 weeks	NA	Previous use of - Ranitidine (dose: NA) - Antibiotics (unmentioned name, dose: NA) with no improvement	3 months	No improvement then discontinued omalizumab	NA	NA
Kirkpatrick et al (2012) ⁵¹	N = 1 of 6	NA	NA	Previous use of 0 (dose: NA) with no improvement	Previous use of - Systemic corticosteroid (unmentioned name, dose: NA) with no improvement	NA	NA	NA	No	- Levothyroxine (dose: 150 g/d) for hypothyroidism due to post ¹³¹ I for Grave's disease	1 month	Complete control, then continue levothyroxine same dose	24 months. After that, levothyroxine was tapered to 125 g/d but relapsed occurred within 3 weeks, so dose was increased to 150 g/d again; complete control	NA
Ivyanskiy et al (2012) ⁷⁶	N = 3 of 19	NA	NA	All cases: previous use of 0 (dose: NA) with no improvement	NA	NA	NA	All cases: - Omalizumab 150 mg sc every 2 weeks	No Previous use of - CsA (dose: NA) with no improvement Previous use of - CsA (dose: NA) - AZA (dose: NA) - MMF (dose: NA) with no improvement in all treatment	No Previous use of - TNF- α inhibitor (dose: NA) with no improvement Previous use of - TNF- α inhibitor (dose: NA) with no improvement	6 months	Complete control then discontinued omalizumab	NA	No
											9 months	Complete control then discontinued omalizumab		
											4 months	Partial improvement then discontinued omalizumab		

(Continued)

Table 4 (Continued).

Study (year)	N = Elderly CU/ Total	Treatment									Duration of treatment	Treatment response	Follow-up after treatment and outcome	Side-effects after treatment
		AH _I			Corticosteroids		LTRA	Omalizumab	Immunosuppressant	Others				
		fgAH _I	sgAH _I	Unspecified AH _I	Systemic	Topical								
Armengot-Carbo et al (2013) ⁸¹	N = 5 of 15	NA	NA	Previous use of 0 (dose: NA) with no improvement	Previous use of - Systemic corticosteroid (unmentioned name, dose: NA) with no improvement NA Previous use of - Systemic corticosteroid (unmentioned name, dose: NA) with no improvement NA Previous use of - Systemic corticosteroid (unmentioned name, dose: NA) with no improvement	NA	NA	- Omalizumab 150 mg sc every 4 weeks for 3 months then 300 mg sc every 4 weeks for other 3 months	Previous use of - CsA (dose: NA) with no improvement	Previous use of -AH ₂ (unmentioned name, dose: NA) with no improvement Previous use of -AH ₂ (unmentioned name, dose: NA) with no improvement NA Previous use of -AH ₂ (unmentioned name, dose: NA) with no improvement	6 months	Partial improvement	NA	Nausea
							- Omalizumab 150 mg sc every 4 weeks for 3 months	3 months			No improvement then discontinued omalizumab	Nausea		
							- Omalizumab 150 mg sc every 2 weeks for 3 months then 150 mg sc every 4 weeks for other 3 months	6 months			Complete control	No		
							- Omalizumab 300 mg sc every 4 weeks for 6 months	6 months			Complete control	No		
							- Omalizumab 150 mg sc every 4 weeks for 3 months	3 months			No improvement then discontinued omalizumab	No		
Zubrinich et al (2019) ⁹²	N = 1 of 4	NA	NA	Previous use of - unspecified AH _I (dose: NA) with partial improvement	Previous use of - Prednisolone (dose: NA) with partial improvement	NA	NA	NA			NA	- Ivermectin (dose: NA) for treatment of <i>Strongyloides</i> infection	NA	Complete control
Case reports														
Urbach (1942) ⁹⁷	N = 1 of 1	NA	NA	NA	NA	NA	NA	NA	NA	- Surgery: neoplasm removal for rectal carcinoma	NA	Complete control	NA	NA

Anderson et al (1991) ⁹⁵	N = 1 of 1	Previous use of - Hydroxyzine (dose: NA) with no improvement	- Terfenadine (dose: NA)	NA	Previous use of - Systemic corticosteroid (unmentioned name, dose: NA) for short course with no improvement	Previous use of - Hydrocortisone cream (dose: NA) with no improvement	NA	NA	NA	- Surgery: neoplasm removal for colon carcinoma	NA	Complete control	60 months	NA
Amoroso et al (1997) ⁶⁹	N = 1 of 1	NA	NA	NA	Previous use of - Betamethasone (dose: 4 mg IV) - Betamethasone (dose: 0.5 mg/d orally) with no improvement	NA	NA	NA	NA	- Surgery: total thyroidectomy for Hashimoto's thyroiditis	NA	Complete control	18 months	NA
Zhang et al (2004) ⁷⁹	N = 1 of 1	Previous use of - Chlorpheniramine (dose: 12 mg/d) with no improvement	NA	NA	- Prednisolone (dose: 10 mg/d) for 3 months and 1 week	NA	NA	NA	- Melphalan (dose: 2 mg) for 1 week followed by - Cyclophosphamide (dose: 50 mg/d) for 3 months for IgA Myeloma	NA	3.25 months	Complete control then discontinued prednisolone, melphalan, and cyclophosphamide	NA, symptom relapsed when myeloma relapsed	NA
Wong et al (2010) ⁵⁶	N = 1 of 1	Previous use of - Diphenhydramine (dose: 50 mg once) with complete control	- Cetirizine (dose: 10 mg/d) for prophylaxis	NA	NA	NA	NA	NA	NA	- Epinephrine auto-injector (dose: NA)	24 months	Marked improvement but 2 months later she acquired another hymenoptera sting, and within 2 weeks developed systemic urticaria when exposing to cold temperature	NA	NA
Baroni et al (2012) ⁸⁵	N = 1 of 1	NA	NA	Previous use of 0 (dose: NA) with no improvement	Previous use of - Systemic corticosteroid (unmentioned name, dose: NA) with no improvement	Previous use of - Topical corticosteroid (unmentioned name, dose: NA) with no improvement	NA	NA	NA	- Surgery: radical prostatectomy for prostate adenocarcinoma	NA	Complete control	24 months	NA

(Continued)

Table 4 (Continued).

Study (year)	N = Elderly CU/ Total	Treatment									Duration of treatment	Treatment response	Follow-up after treatment and outcome	Side-effects after treatment
		AH _I			Corticosteroids		LTRA	Omalizumab	Immunosuppressant	Others				
		fgAH _I	sgAH _I	Unspecified AH _I	Systemic	Topical								
Hui-Hui et al (2012) ⁸⁴	N = 1 of 1	NA	Previous use of - Loratadine (dose: NA, taken once every other day) for 4 months with partial improvement	NA	NA	NA	NA	NA	NA	- Surgery: right middle lobectomy for lung cancer removal	NA	Complete control	6 months	NA
Zimmer et al (2016) ⁸²	N = 1 of 1	NA	NA	Previous use of -AH _I (unmentioned name, dose: up to 4 times of licensed dose) with no improvement	NA	NA	NA	- Omalizumab 300 mg sc every 4 weeks	NA	NA	4 months	Marked improvement then discontinued omalizumab	5 months, then relapse occurred	No
Sussman et al (2016) ⁶⁰	N = 1 of 1	Previous use of - Hydroxyzine (dose: 25–200 mg/d) - Diphenhydramine (dose: 25–200 mg/d) - Doxepin (dose: 25–125 mg/d) with no improvement in all treatment but caused sedation	Previous use of - Cetirizine (dose: 10–40 mg/d) - Loratadine (dose: 10 mg/d) with no improvement in all treatment - Cetirizine (dose: 20 mg/d)	Previous use of 0 (dose: NA dosage as needed) with no improvement	Previous use of - Prednisolone (dose: 5–40 mg/d) with no improvement - Prednisolone (dose: tapering doses from before study until discontinued)	NA	Previous use of - Montelukast (dose: 10 mg/d) with no improvement	- Omalizumab 150 mg sc every 4 weeks	Previous use of - HCQ (dose: 400 mg/d) for 2 months - CsA (dose: 300 mg/d) for 2 months with no improvement in all treatment	Previous use of - Ranitidine (dose: 300 mg/d) with no improvement - IVIG (dose: NA, discontinued due to hemolytic reaction) Both with partial improvement	36 months	Marked improvement after 1 week then continued same dose of omalizumab but stopped taking prednisolone, resulting in low daily UAS7 scores. After 36 months, symptoms became severe, required longer courses and doses of prednisolone. Moreover, omalizumab was increased to 300 mg sc every 4 weeks to maintain low UAS7.	NA	NA
Kasperska-Zajac et al (2016) ⁹¹	N = 1 of 1	NA	NA	Previous use of 0 (high dose) with no improvement	Previous use of - Prednisolone (dose: up to 15 mg) for the past 3–10 years with no improvement	NA	NA	- Omalizumab 300 mg sc	NA	NA	NA	Complete control after 1 dose of omalizumab then continued with omalizumab 150–300 mg every 5–6 weeks	NA	No

Aldasouqi et al (2018) ⁹⁶	N = 1 of 1	NA	NA	NA	NA	NA	NA	NA	NA	- Surgery: parathyroidectomy for primary hyperparathyroidism caused by large parathyroid adenoma	NA	Complete control	NA	NA
Pannofino (2018) ⁵⁸	N = 1 of 1	NA	- Rupatadine (dose: 10 mg twice daily) for 20 days then continue with 10 mg/d for 6 months then discontinued	Previous use of - unspecified AH ₁ (dose: NA) with no improvement	Previous use of - Oral corticosteroid (unmentioned name, dose: NA) with no improvement	NA	NA	- Omalizumab 300 mg sc every 4 weeks	NA	NA	6 months	Complete control then discontinued omalizumab	12 months	NA

Notes: ^aIt should be noted that the study of Kaplan et al included 12 CU patients (with 2 elderly patients) to be received placebo for 4 weeks and then omalizumab for 16 weeks. Omalizumab was injected every 2 weeks or every 4 weeks, dosed according to the patient's body weight, and serum IgE at the screening visit.

Abbreviations: AH1, H1-antihistamine; AH2, H2-antihistamine; AZA, azathioprine; CsA, cyclosporine; d, day; fgAH1, first generation antihistamine; HCQ, hydroxychloroquine; IM, intramuscular; IV, intravenous; IVIG, intravenous immunoglobulin; LTRA, Leukotriene-receptor antagonist; mg, milligram; MMF, mycophenolate mofetil; MTX, methotrexate; NA, not available/not applicable; sc, subcutaneous; SD, symptomatic dermatographism; sgAH1, second generation antihistamine; TNF- α inhibitor, tumor necrosis factor- α inhibitors; UAS7, Weekly Urticarial Activity Score.

Table 5 Comparison of the Reported Demographic and Clinical Characteristics of Elderly Patients with Chronic Urticaria (CU) with Those of Non-Elderly

Clinical features: N/Total (%)	Elderly (our systematic review)	Non-elderly
Demographic Data		
Prevalence of CU in population	22,900/9,757,210 (0.2) – 13,476/488,145 (2.8) ^{29,33,35,46}	6019/7,555,991 (0.1) – 90/2613 (3.4) ^{9,19,29,30,33,98,134–140}
CSU proportion in CU	127/153 (83.0) – 63/65 (96.9) ^{10,20,45}	145/220 (66.0) – 215/231 (93.1) ^{26,34,74,108–111,141–146}
CIndU proportion in CU	2/65 (3.1) – 26/153 (17.0) ^{10,20,32,45}	17/329 (5.2) – 75/220 (34.0) ^{26,74,108–111,141–146}
Sex ratio (Male: Female)	1: 0.9–3.3 ^{10–12,20–25,30–33,37,39,40,45,90}	1: 1.0–5.7 ^{10,12,19,28–30,33,34,36–38,40,41,74,100,109,114,130,131,134,136,139,142–144,147–163}
Clinical presentation		
Wheal alone	10/30 (33.3) – 86/99 (86.9) ^{10,12,20,37,40,90}	96/330 (29.1) – 77/102 (75.5) ^{12,20,40,107,109,136,141,143,147,149,163–168}
Wheal with angioedema	13/99 (13.1) – 20/30 (66.7) ^{10,12,20,37,40,90}	17/248 (6.9) – 152/199 (76.4) ^{12,28,36–40,74,109,111,120,136,141,143,147,149,158,159,163,165–173}
Wheal with anaphylaxis ^a	1/1 (100.0) ⁵⁶	0/2,175 (0.0) ^{28,174,175}
Personal history of atopy	2/92 (2.2) – 9/26 (34.6) ^{10,11,20,37,45,64,90}	171/13,479 (1.3) – 101/147 (68.7) ^{11,12,28,34–38,74,100,106,114,147,159,160,163,176–179}
Comorbidities		
Gastrointestinal diseases	5/104 (4.8) – 708,415/985,278 (71.9) ^{20,64}	127/12,185 (1.0) – 145/330 (44.0) ^{12,28,100,111,131,178,180–182}
Metabolic syndrome	21/63 (33.3) – 44/92 (47.8) ^{20,90}	276/12/185 (2.3) – 1,741/11,261 (15.5) ^{100,114,116}
Thyroid diseases	1/67 (1.5) – 19/99 (19.2) ^{10,20,37,45}	34/13,479 (0.3) – 20/47 (42.5) ^{12,28,30,35–37,67,70,100,153,159,165,170–172,178,183,184}
Autoimmune diseases	8/63 (12.7) ⁹⁰	40/12,185 (0.3) – 25/209 (12.0) ^{30,100,153,159,170,172}
Psychiatric problems		
Anxiety disorders	NA	266/13,479 (2.0) – 24/30 (80.0) ^{35,139,185–189}
Depression & other psychiatric problems	2/99 (2.0) – 2/26 (7.7) ^{37,45,65}	121/12,185 (1.0) – 21/30 (70.0) ^{12,30,36,37,100,139,148,154,159,185–187,189–192}
Malignancies		
Hematologic malignancy ^b	33/3,615 (0.9) ¹⁹	80/36,910 (0.2) – 25/9,105 (0.3) ^{18,19}
Other	415/3,615 (11.5) – 11/92 (12.0) ^{19,20}	231/9,105 (0.3) – 330/13,479 (2.5) ^{18,19,35,148}
Most common subtype of CIndU	Symptomatic dermographism ^{10,20,45}	Symptomatic dermographism ^{10,36,37,74,108,111,193–195}
Laboratory investigations		
Positive antinuclear antibodies	13/63 (20.6) of CSU ¹⁰	248/12,778 (1.9) – 131/195 (67.2) of CSU ^{10,120,155,158,160,196,197}
Elevated erythrocyte sedimentation rate	18/63 (28.6) ¹⁰	3/184 (1.6) – 65/133 (48.9) ^{10,74,155,160,165,172,178,198}
Elevated total serum IgE ^c	NA	14/330 (4.2) – 34/62 (54.8) ^{12,28,36,74,165,199–201}
Positive ASST	11/61 (18.0) – 3/5 (60.0) of CSU ^{20,37,40,42}	12/45 (26.7) – 49/67 (73.1) of CSU ^{10,28,36,37,40,74,108,111,130,142,150,155,156,160,168,196,202–211}
Abnormal thyroid function test ^c	NA	20/330 (6.1) – 20/66 (30.3) ^{12,38,67,70,78,198,212,213}
Abnormal free T3 ^c	NA	1/56 (1.8) – 99/165 (60.0) ^{74,214}
Abnormal free T4 ^c	NA	97/165 (58.8) ⁷⁴
Abnormal TSH ^c	NA	2/56 (3.6) – 99/167 (59.3) ^{74,165,171,183,214,215}
Positive thyroid autoantibodies	3/24 (12.5) – 21/63 (33.3) ^{10,11,40}	3/79 (3.8) – 27/47 (57.5) ^{10,11,36,40,67,70,71,73,74,106,109,120,130,153,155–157,160,161,163,165,168,170–173,183,184,196,198,199,201–203,207,209–237}
Positive HBsAg	8/63 (12.7) ¹⁰	0/121 (0.0) – 2/56 (3.6) ^{10,28,111,128,129,192,238}

(Continued)

Table 5 (Continued).

Clinical features: N/Total (%)	Elderly (our systematic review)	Non-elderly
Duration of disease prior to diagnosis (years)	0.2–2.0 ^{39,60,67,69,79,85,87}	3.2–6.3 ^{87,172}
Treatment		
Response to 1 st line (standard dose AH ₁)	17.045/99 (45.5) – 23/26 (88.5) ^{37,38,45}	164/516 (31.8) – 163/248 (65.9) ^{36–39,160,170}
Needed 2 nd line	3/26 (11.5) – 24/96 (25.0) ^{37,45}	36/335 (10.8) – 199/569 (34.9) ^{36,37,170,172}
Needed 3 rd line	5/32 (15.6) – 28/95 (29.5) ^{37,40}	36/361 (10.0) – 93/329 (28.3) ^{36,37,40,74,108,159,172,178}

Notes: ^aWheal with anaphylaxis in elderly was found in only one case report of cold urticaria. ^bIt should be noted that the only retrospective study which reported malignancy in population was from Chen et al ^cProportion of elevated IgE, abnormal thyroid function test, free T3, free T4, and TSH in elderly patients were reported in only case reports and case series. No prospective or retrospective cohort study was found.

Abbreviations: ASST, autologous serum skin test; CIndU, chronic inducible urticaria; CSU, chronic spontaneous urticaria; CU, chronic urticaria; HBsAg, hepatitis B surface antigen; NA, not available/not applicable; TSH, thyroid stimulating hormone.

depression to be common in adult CU, while elderly CU was reported mainly in dementia and other non-specific psychological problems.¹⁰⁰

The high rate of malignancies, both hematologic and non-hematologic, in the present study may be explained by the advanced age. Most studies reported CU patients to be at high risk of developing cancers, and the incidence of cancer also increased with age.^{19,89,125,126} A possible mechanism is alteration of the immune system by the tumor.¹²⁶ Age-appropriate malignancy screening is, therefore, strongly encouraged for early detection and treatment, which will improve the outcomes of both cancer and urticaria.^{89,93,97,126}

The high prevalence of thyroid autoantibodies in both geriatric and adult CU suggests the relationship between CU and thyroid autoimmunity,^{10,11,40,67,70,120,123,127} even though this study and the previous report showed no difference of thyroid autoantibodies between the two groups.¹¹ Focusing on infections, hepatitis B virus was the only infection in this study that was reported at higher prevalence (12.7%) than in previously reported general CU patients (0–3.6%).^{128,129} There was no difference in other laboratory findings, such as ESR, ANA, and total serum IgE levels. However, elderly CSU was reported to have a relatively lower proportion of positive ASST than adult CSU, as in the study by Magen et al.²⁰

Treatment of CU in elderly patients usually follows the same guidelines as the general population. SgAH₁ is recommended as the first-line treatment for elderly CU. The regular dose of SgAH₁ is generally sufficient to achieve complete control in most patients, with a higher proportion of response in elderly CU than adults. This was in line with the finding of a lower rate of ASST in the elderly. As ASST positivity correlates with higher severity and longer duration of disease of CSU,^{127,130–132} geriatric patients may have less severe CU symptoms than adult CU, resulting in fewer associated angioedema and good response to standard treatment. Updosing to a higher dose or 4-times was also reported the good efficacy in SgAH₁. For patients who fail on antihistamines, successful symptom control has been achieved by the use of omalizumab 150–300 mg every 2–4 weeks.

Some patients with autoimmune thyroiditis and hypothyroid were treated by levothyroxine, which also helps in improving urticaria.^{51,67,73} The risks and benefits of these third-line drugs have not been sufficiently explored and additional studies are needed.^{7,83} Another treatment strategy that significantly improved CU symptoms was treatment of secondary causes concurrent with standard treatments, especially in aging patients in whom autoimmune disorders, malignancies and infections are more common. A systematic review by Kolchir et al¹³³ found CSU to be quite common in patients with strongyloidiasis. Its pathogenesis may be due to eosinophil and complement activation leading to skin mast cell activation. Magen et al⁶³ and Zubrinich et al⁹² reported an association between *H. Pylori* infection, *Strongyloides* infection, and CU. Treatment with standard antiparasitic drugs yielded complete control.^{63,92,133} Therefore, treatment of these associated comorbidities, including infection, might result in a better CU control.

Table 6 Quality and Risk of Bias Assessment of Included Articles in Systematic Review

A. Randomized controlled trials														
Study, year ^{Ref}	Random sequence generation (selection bias)			Allocation concealment		Blinding of participants and personnel			Blinding of outcome assessment		Incomplete outcome data		Selective reporting	
Staubach et al, 2016 ²³⁹	+			+		+			+		+		+	
Kaplan et al, 2005 ²⁴⁰	?			?		+			+		+		+	
Goldsobel et al, 1986 ⁶⁸	+			+		+			+		+		+	
B. Non-randomized controlled trials														
Study, year ^{Ref}	Criteria								Additional criteria in the case of comparative study					
	A stated aim of the study	Inclusion of consecutive patients	Prospective collection of data	End point appropriate to the study aim	Unbiased evaluation of end points	Follow-up period appropriate	Loss to follow-up not exceeding 5%	Prospective calculation of the study size	A control group having the criterion standard intervention	Contemporary groups	Baseline equivalence of groups	Prospective calculation of the sample size	Statistical analyses adapted to the study design	Total
Martina et al, 2021 ⁹⁰	2	2	2	2	0	2	0	0	-	-	-	-	-	10
Napolitano et al, 2021 ⁴⁵	2	2	2	2	0	2	0	0	-	-	-	-	-	10
Gaber et al, 2020 ⁴⁶	2	2	2	2	0	2	2	0	-	-	-	-	-	12
Chung et al, 2020 ⁷⁴	2	2	2	2	0	2	0	0	-	-	-	-	-	10
Seo et al, 2019 ³²	2	2	2	2	0	2	0	0	-	-	-	-	-	10
Zubrinich et al, 2019 ⁹²	1	1	1	2	0	2	0	0	-	-	-	-	-	7
Wertenteil et al, 2019 ³³	2	2	2	2	0	0	0	0	-	-	-	-	-	8
Jankowska-Konsur et al, 2019 ³⁴	2	2	2	2	0	0	0	0	-	-	-	-	-	8
Jo et al, 2019 ³⁹	2	2	2	2	0	2	0	0	-	-	-	-	-	10
Curto-Barredo et al, 2019 ³⁷	2	2	2	2	0	2	0	0	-	-	-	-	-	10
Eun et al, 2018 ³¹	2	2	2	2	0	2	2	0	-	-	-	-	-	12
Nettis et al, 2018 ⁴⁰	2	2	2	2	0	2	0	0	-	-	-	-	-	10
Napolitano et al, 2018 ⁹³	2	2	2	2	0	2	0	0	-	-	-	-	-	10
Chanprapaph et al, 2018 ⁶⁰	2	2	2	2	0	2	0	0	-	-	-	-	-	10
Curto-Barredo et al, 2018 ³⁶	2	2	2	2	0	2	0	0	-	-	-	-	-	10
Pannofino, 2018 ⁵⁸	2	0	2	1	0	2	0	0	-	-	-	-	-	7
Aldasouqi, 2018 ⁹⁶	2	0	2	1	0	1	0	0	-	-	-	-	-	6
Kulthanan et al, 2017 ⁵⁷	2	2	2	2	0	2	0	0	-	-	-	-	-	10
Lee et al, 2017 ⁶⁴	2	2	2	2	0	2	0	0	-	-	-	-	-	10
Chu et al, 2017 ³⁰	2	2	2	2	0	2	0	0	-	-	-	-	-	10
Ali, 2016 ¹⁵²	2	2	2	2	0	2	2	0	0	2	2	0	2	20
Chuamanochan et al, 2016 ¹⁰	2	2	2	2	0	2	0	0	-	-	-	-	-	10
Kasperska-Zajac et al, 2016 ⁹¹	2	2	2	2	0	2	0	0	-	-	-	-	-	10

Lapi et al, 2016 ³⁵	2	2	2	2	0	2	0	0	-	-	-	-	-	10
Zimmer et al, 2016 ⁴²	1	0	0	2	0	2	0	0	-	-	-	-	-	5
Sussman et al, 2016 ⁴⁰	1	0	0	2	0	2	0	0	-	-	-	-	-	5
Romano et al, 2015 ⁴²	2	2	2	2	0	2	0	0	-	-	-	-	-	10
Sugiyama et al, 2015 ⁷³	2	2	2	2	0	2	0	0	-	-	-	-	-	10
Uysal et al, 2014 ⁴¹	2	2	2	2	0	2	2	0	-	-	-	-	-	12
Ban et al, 2014 ¹¹	2	2	2	2	0	2	0	0	-	-	-	-	-	10
Vikramkumar et al, 2014 ⁴²	2	2	2	2	0	0	0	0	-	-	-	-	-	8
Magen et al, 2013 ²⁰	2	2	2	2	0	2	0	0	-	-	-	-	-	10
Song et al, 2013 ⁵⁵	2	2	2	2	0	2	0	0	-	-	-	-	-	10
Magen et al, 2013 ²⁰	2	2	2	2	0	2	0	0	-	-	-	-	-	10
Lefevre et al, 2013 ⁷⁵	2	2	2	2	0	2	0	0	-	-	-	-	-	10
Hiragun et al, 2012 ³⁸	2	2	2	2	0	2	0	0	-	-	-	-	-	10
Armengot-Carbo et al, 2013 ⁸¹	1	1	1	2	0	2	0	0	-	-	-	-	-	7
Kirkpatrick et al, 2012 ⁵¹	2	1	2	2	0	2	0	0	-	-	-	-	-	9
Chen et al, 2012 ¹⁹	2	2	2	2	0	2	0	0	-	-	-	-	-	10
Krupashankar et al, 2012 ²⁸	2	2	2	2	0	2	2	0	-	-	-	-	-	12
Ivyanskiy et al, 2012 ⁷⁶	1	1	1	2	0	1	0	0	-	-	-	-	-	6
Hui-hui et al, 2012 ⁸⁴	2	0	0	2	0	2	0	0	-	-	-	-	-	6
Baroni et al, 2012 ⁸⁵	1	1	1	2	0	2	0	0	-	-	-	-	-	7
Groffik et al, 2011 ⁴⁹	1	1	1	2	0	2	0	0	-	-	-	-	-	7
Godse, 2011 ⁴⁸	2	2	2	2	0	2	0	0	-	-	-	-	-	10
Asero et al, 2011 ⁸⁶	2	2	2	2	0	0	0	0	-	-	-	-	-	8
Sagi et al, 2011 ⁸³	2	2	2	2	0	2	0	0	-	-	-	-	-	10
Metz et al, 2011 ⁵²	1	1	1	2	0	2	0	0	-	-	-	-	-	7
Mitzel-Kaoukhov et al, 2010 ⁵³	2	2	2	2	0	2	2	0	-	-	-	-	-	12
Mozena et al, 2010 ⁷²	2	2	2	2	0	0	0	0	-	-	-	-	-	8
Perez et al, 2010 ²⁴¹	2	2	2	2	0	2	0	0	-	-	-	-	-	10
Wong et al, 2010 ⁵⁶	1	0	0	2	0	2	0	0	-	-	-	-	-	5
Staubach et al, 2009 ⁸⁰	2	2	2	2	0	0	0	0	-	-	-	-	-	8
Kaplan et al, 2008 ⁵⁰	2	2	2	2	1	2	2	0	0	2	2	0	2	19
Katsarou-Katsari et al, 2008 ⁴⁴	2	2	2	2	2	0	0	0	-	-	-	-	-	10
Feibelmann, 2007 ⁷¹	2	2	2	2	0	0	0	0	-	-	-	-	-	8
Manganoni et al, 2007 ⁶⁹	1	1	1	2	0	2	0	0	-	-	-	-	-	7
Cebeci et al, 2006 ⁷⁰	2	2	2	2	0	0	0	0	-	-	-	-	-	8
McGirt et al, 2006 ⁹⁴	2	2	2	2	0	2	0	0	-	-	-	-	-	10
Sanada et al, 2005 ²⁴²	2	2	2	2	0	2	2	0	-	-	-	-	-	12
Yang et al, 2005 ⁴¹	2	2	2	2	0	0	0	0	-	-	-	-	-	8

(Continued)

Table 6 (Continued).

A. Randomized controlled trials														
Study, year ^{Ref}	Random sequence generation (selection bias)			Allocation concealment		Blinding of participants and personnel			Blinding of outcome assessment		Incomplete outcome data		Selective reporting	
O'Donnell, 2005 ⁷⁷	2	2	2	2	0	0	0	0	-	-	-	-	-	8
Gaig et al, 2004 ²⁹	2	2	2	2	0	0	0	0	-	-	-	-	-	8
Zhang et al, 2004 ⁷⁹	1	0	0	2	0	1	0	0	-	-	-	-	-	4
Asero et al, 2003 ⁷⁸	2	2	2	2	0	0	0	0	-	-	-	-	-	8
O'Donnell, 1998 ⁵⁴	2	2	2	2	0	2	2	0	-	-	-	-	-	12
Amoroso, 1997 ⁶⁹	1	0	0	2	0	2	0	0	-	-	-	-	-	5
Rumbyrt et al, 1995 ⁸⁸	2	2	2	2	0	2	2	0	-	-	-	-	-	12
Hashiro et al, 1994 ²⁷	2	2	2	2	0	0	0	0	-	-	-	-	-	8
Barlow et al, 1993 ²⁶	2	2	2	2	0	2	0	0	-	-	-	-	-	10
Anderson, 1991 ⁹⁵	1	0	0	1	0	2	0	0	-	-	-	-	-	4
Lindelof et al, 1990 ¹⁴⁸	2	2	2	2	0	2	0	0	-	-	-	-	-	10
Reisman et al, 1989 ²⁴³	2	2	2	2	0	2	2	0	-	-	-	-	-	12
Dover, 1988 ⁴³	2	2	2	2	0	2	0	0	-	-	-	-	-	10
Lanigan et al, 1987 ⁶⁶	2	0	0	1	0	0	0	0	-	-	-	-	-	3
Mekkes et al, 1986 ²⁵	2	2	2	2	0	2	0	0	-	-	-	-	-	10
Greene et al, 1985 ²⁴⁴	2	2	2	2	2	2	2	0	0	2	2	0	2	20
Lanigan et al, 1984 ⁶⁵	1	1	2	2	0	0	0	0	-	-	-	-	-	6
Leznoff et al, 1983 ⁶⁷	1	2	2	2	0	2	2	0	-	-	-	-	-	11
Vaida et al, 1983 ⁸⁷	2	2	2	2	0	2	0	0	-	-	-	-	-	10
Juhlin, 1981 ¹²	1	0	2	2	0	0	0	0	-	-	-	-	-	5
Urbach, 1942 ⁹⁷	1	0	0	1	0	0	0	0	-	-	-	-	-	2

Notes: +, low risk of bias; -, high risk of bias; ?, unclear risk of bias; 0, not reported; 1, reported but inadequate; 2, reported and adequate.

Limitations

Most of the included articles were retrospective studies, case reports, and case series, which are inherently classified as having a lower level of evidence (Table 6). Only three randomized controlled trials were eligible to be included in the analysis, hence, the number of control groups was low. Furthermore, only a few studies had a study population consisting only of elderly patients. These limitations further underscore the potential value of this study and make clinicians more aware that more prospective studies are needed on cases of CU in the elderly.

Conclusions

This systematic review found that the prevalence CU ranges between 0.2–2.8% in the elderly population. CSU was still the most common type, and exhibited a female predominance. Compared with adult CU, a lower rate of atopy, more age-related comorbidities including metabolic syndrome, autoimmune disorders, and malignancies, a lower rate of associated angioedema, and lower ASST positivity, were reported in elderly CU. The use of antihistamines often yielded good results as first-line treatment. Omalizumab was effective in AH₁-resistant cases, and other differential diagnosis should be considered in patients refractory to standard treatment. More prospective studies are necessary to further elucidate the characteristics of the disease in this age group.

Abbreviations

AH₁, H₁-antihistamine; CIndU, Chronic inducible urticaria; CSU, Chronic spontaneous urticaria; CsA, Cyclosporine; CU, Chronic urticaria; ESR, Erythrocyte sedimentation rate; fgAH₁, First generation H₁-antihistamine; GI, Gastrointestinal; *H. pylori*, *Helicobacter pylori*; IVIG, Intravenous immunoglobulin; MTX, Methotrexate; RCT, Randomized controlled trial; SD, Symptomatic dermographism; sgAH₁, Second generation H₁-antihistamine.

Acknowledgment

The authors gratefully acknowledge Saowalak Hunnangkul, PhD for her assistance with statistical analysis, and for her advice regarding the systematic review process.

Disclosure

This research did not receive any specific grants from funding agencies in the public, commercial, or not-for-profit sectors for the present study. All of the authors report no conflicts of interest in this work.

References

1. Wamble DE, Ciarametaro M, Dubois R. The effect of medical technology innovations on patient outcomes, 1990-2015: results of a physician survey. *J Manag Care Spec Pharm*. 2019;25(1):66–71. doi:10.18553/jmcp.2018.18083
2. Buxbaum JD, Chernew ME, Fendrick AM, Cutler DM. Contributions of public health, pharmaceuticals, and other medical care To US life expectancy changes, 1990-2015. *Health Aff*. 2020;39(9):1546–1556.
3. United Nations Department of Economic and Social Affairs Population Division. World Population Ageing 2020 Highlights: living arrangements of older persons. New York: United Nations Publication; 2020:1. Available from: https://www.un.org/development/desa/pd/sites/www.un.org/development/desa/pd/files/undesa_pd-2020_world_population_ageing_highlights.pdf. Accessed Oct 12, 2021.
4. World Health Organization (WHO). Decade of healthy ageing: baseline report: summary. Geneva: World Health Organization; 2021:20. Available from: <https://www.who.int/publications/i/item/9789240023307>. Accessed Oct 12, 2021.
5. Ward JR, Bernhard JD. Willan's itch and other causes of pruritus in the elderly. *Int J Dermatol*. 2005;44(4):267–273.
6. Thaipisuttikul Y. Pruritic skin diseases in the elderly. *J Dermatol*. 1998;25(3):153–157.
7. Zuberbier T, Abdul latiff AH, Abuzakouk M, et al. The International EAACI/GA²LEN/EuroGuiDerm/APAAACI Guideline for the Definition, Classification, Diagnosis and Management of Urticaria. *Allergy*. 2022;77(3):734–766.
8. Maurer M, Eyerich K, Eyerich S, et al. Urticaria: collegium Internationale Allergologicum (CIA) Update 2020. *Int Arch Allergy Immunol*. 2020;181(5):321–333.
9. Saini S, Shams M, Bernstein JA, Maurer M. Urticaria and Angioedema Across the Ages. *J Allergy Clin Immunol Pract*. 2020;8(6):1866–1874.
10. Chuamanochan M, Kulthanan K, Tuchinda P, Chularojanamontri L, Nuchkull P. Clinical features of chronic urticaria in aging population. *Asian Pac J Allergy Immunol*. 2016;34(3):201–205. doi:10.12932/AP0708
11. Ban G-Y, Kim M-Y, Yoo H-S, et al. Clinical features of elderly chronic urticaria. *Korean J Intern Med*. 2014;29(6):800–806. doi:10.3904/kjim.2014.29.6.800
12. Juhlin L. Recurrent urticaria: clinical investigation of 330 patients. *Br J Dermatol*. 1981;104(4):369–381. doi:10.1111/j.1365-2133.1981.tb15306.x

13. Al-Thani MH, Al-Thani AAM, Cheema S, et al. Prevalence and determinants of metabolic syndrome in Qatar: results from a National Health Survey. *BMJ Open*. 2016;6(9):e009514.
14. Bonomini F, Rodella LF, Rezzani R. Metabolic syndrome, aging and involvement of oxidative stress. *Aging Dis*. 2015;6(2):109–120.
15. Syed MA, Alnuaimi AS, Zainel AJ, Qotba HA. Prevalence of non-communicable diseases by age, gender and nationality in publicly funded primary care settings in Qatar. *BMJ Nutr Prev Health*. 2019;2(1):20–29.
16. Gunalan P, Indradevi R, Oudeacoumar P, et al. Pattern of skin diseases in geriatric patients attending tertiary care centre. *J Evol Med Dent Sci*. 2017;6:1566–1570.
17. Kolkhir P, Metz M, Altrichter S, Maurer M. Comorbidity of chronic spontaneous urticaria and autoimmune thyroid diseases: a systematic review. *Allergy*. 2017;72(10):1440–1460.
18. Kim BR, Yang S, Choi JW, Choi CW, Youn SW. Epidemiology and comorbidities of patients with chronic urticaria in Korea: a nationwide population-based study. *J Dermatol*. 2018;45(1):10–16.
19. Chen YJ, Wu CY, Shen JL, Chen TT, Chang YT. Cancer risk in patients with chronic urticaria: a population-based cohort study. *Arch Dermatol*. 2012;148(1):103–108.
20. Magen E, Mishal J, Schlesinger M. Clinical and laboratory features of chronic idiopathic urticaria in the elderly. *Int J Dermatol*. 2013;52(11):1387–1391.
21. Flohr C, Hay R. Putting the burden of skin diseases on the global map. *Br J Dermatol*. 2021;184(2):189–190.
22. Maurer M, Ortonne J-P, Zuberbier T. Chronic urticaria: an internet survey of health behaviours, symptom patterns and treatment needs in European adult patients. *Br J Dermatol*. 2009;160(3):633–641.
23. Gonçalo M, Giménez-Arnau A, Al-Ahmad M, et al. The global burden of chronic urticaria for the patient and society. *Br J Dermatol*. 2021;184(2):226–236.
24. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev*. 2015;4(1):548.
25. Mekkes JR, van der Schaar, WW, Bos JD. Anamnese en diagnostiek van chronische urticaria. *Ned Tijdschr Geneesk*. 1986;130:1801–1805.
26. Barlow RJ, Warburton F, Watson K, Black AK, Greaves MW. Diagnosis and incidence of delayed pressure urticaria in patients with chronic urticaria. *J Am Acad Dermatol*. 1993;29(6):954–958.
27. Hashiro M, Okumura M. Anxiety, depression, psychosomatic symptoms and autonomic nervous function in patients with chronic urticaria. *J Dermatol Sci*. 1994;8(2):129–135.
28. Krupashankar DS, Shashikala K, Madala R. Clinical and investigative assessment of patients with positive versus negative autologous serum skin test: a study of 80 South Indian patients. *Indian J Dermatol*. 2012;57(6):434–438.
29. Gaig P, Olona M, Muñoz Lejarazu D, et al. Epidemiology of urticaria in Spain. *J Investig Allergol Clin Immunol*. 2004;14(3):214–220.
30. Chu CY, Cho YT, Jiang JH, Lin EI, Tang CH. Epidemiology and comorbidities of patients with chronic urticaria in Taiwan: a nationwide population-based study. *J Dermatol Sci*. 2017;88(2):192–198.
31. Eun SJ, Lee JY, Kim DY, Yoon HS. Natural course of new-onset urticaria: results of a 10-year follow-up, nationwide, population-based study. *Allergol Int*. 2019;68(1):52–58.
32. Seo JH, Kwon JW. Epidemiology of urticaria including physical urticaria and angioedema in Korea. *Korean J Intern Med*. 2019;34(2):418–425.
33. Wertenteil S, Strunk A, Garg A. Prevalence estimates for chronic urticaria in the United States: a sex- and age-adjusted population analysis. *J Am Acad Dermatol*. 2019;81(1):152–156.
34. Jankowska-Konsur A, Reich A, Szepletowski J. Polish Chronic Urticaria Working G. Clinical characteristics and epidemiology of chronic urticaria: a nationwide, multicentre study on 1091 patients. *Postepy Dermatol Alergol*. 2019;36(2):184–191.
35. Lapi F, Cassano N, Pegoraro V, et al. Epidemiology of chronic spontaneous urticaria: results from a nationwide, population-based study in Italy. *Br J Dermatol*. 2016;174(5):996–1004.
36. Curto-Barredo L, Archilla LR, Vives GR, Pujol RM, Giménez-Arnau AM. Clinical features of chronic spontaneous urticaria that predict disease prognosis and refractoriness to standard treatment. *Acta Derm Venereol*. 2018;98(7):641–647.
37. Curto-Barredo L, Pujol RM, Roura-Vives G, Gimenez-Arnau AM. Chronic urticaria phenotypes: clinical differences regarding triggers, activity, prognosis and therapeutic response. *Eur J Dermatol*. 2019;29(6):627–635.
38. Hiragun M, Hiragun T, Mihara S, Akita T, Tanaka J, Hide M. Prognosis of chronic spontaneous urticaria in 117 patients not controlled by a standard dose of antihistamine. *Allergy*. 2013;68(2):229–235.
39. Jo YH, Yoo HW, Kim SH, Kim YM, Kim HY. Clinical characteristics and treatment response of chronic spontaneous urticaria according to age: a single-center Korean study. *Asian Pac J Allergy Immunol*. 2019. doi:10.12932/AP-050719-0594
40. Nettis E, Cegolon L, Di Leo E, Canonica WG, Detoraki A. Omalizumab in elderly patients with chronic spontaneous urticaria: an Italian real-life experience. *Ann Allergy Asthma Immunol*. 2018;120(3):318–323.
41. Yang HY, Sun CC, Wu YC, Wang JD. Stress, insomnia, and chronic idiopathic urticaria—a case-control study. *J Formos Med Assoc*. 2005;104(4):254–263.
42. Vikramkumar AG, Kuruvila S, Ganguly S. Autologous serum skin test as an indicator of chronic autoimmune urticaria in a tertiary care hospital in South India. *Indian Dermatol Online J*. 2014;5(Suppl 2):S87–S91.
43. Dover JS, Black AK, Ward AM, Greaves MW. Delayed pressure urticaria. Clinical features, laboratory investigations, and response to therapy of 44 patients. *J Am Acad Dermatol*. 1988;18(6):1289–1298.
44. Katsarou-Katsari A, Makris M, Lagogianni E, Gregoriou S, Theoharides T, Kalogeromitros D. Clinical features and natural history of acquired cold urticaria in a tertiary referral hospital: a 10-year prospective study. *J Eur Acad Dermatol Venereol*. 2008;22(12):1405–1411.
45. Napolitano M, Fabbrocini G, Stingeni L, Patruno C. Prevalence of Chronic Inducible Urticaria in Elderly Patients. *J Clin Med*. 2021;10(2):247.
46. Gaber M, Hasanin AZ. Skin diseases in elderly. *Menoufia Med J*. 2020;33(1):272–276.
47. Dávila I, Del Cuvillo A, Mullo J, et al. Use of second generation H1 antihistamines in special situations. *J Investig Allergol Clin Immunol*. 2013;23(Suppl 1):S1–S16.
48. Godse KV. Omalizumab in treatment-resistant chronic spontaneous urticaria. *Indian J Dermatol*. 2011;56(4):444.
49. Groffik A, Mitzel-Kaoukhov H, Magerl M, Maurer M, Staubach P. Omalizumab—an effective and safe treatment of therapy-resistant chronic spontaneous urticaria. *Allergy*. 2011;66(2):303–305.

50. Kaplan AP, Joseph K, Maykut RJ, Geba GP, Zeldin RK. Treatment of chronic autoimmune urticaria with omalizumab. *J Allergy Clin Immunol*. 2008;122(3):569–573.
51. Kirkpatrick CH. A mechanism for urticaria/angioedema in patients with thyroid disease. *J Allergy Clin Immunol*. 2012;130(4):988–990.
52. Metz M, Altrichter S, Ardelean E, et al. Anti-immunoglobulin E treatment of patients with recalcitrant physical urticaria. *Int Arch Allergy Immunol*. 2011;154(2):177–180.
53. Mitzel-Kaoukhov H, Staubach P, Müller-Brenne T. Effect of high-dose intravenous immunoglobulin treatment in therapy-resistant chronic spontaneous urticaria. *Ann Allergy Asthma Immunol*. 2010;104(3):253–258.
54. O'Donnell BF, Barr RM, Black AK, et al. Intravenous immunoglobulin in autoimmune chronic urticaria. *Br J Dermatol*. 1998;138(1):101–106.
55. Song CH, Stern S, Giruparajah M, Berlin N, Sussman GL. Long-term efficacy of fixed-dose omalizumab for patients with severe chronic spontaneous urticaria. *Ann Allergy Asthma Immunol*. 2013;110(2):113–117.
56. Wong CG, Borici-Mazi R. Delayed-onset cold anaphylaxis after hymenoptera sting. *Ann Allergy Asthma Immunol*. 2012;109(1):77–78.
57. Kulthanan K, Tuchinda P, Chularojanamontri L, Likitwattanarak C, Ungakornpairote C. Omalizumab therapy for treatment of recalcitrant chronic spontaneous urticaria in an Asian population. *J Dermatolog Treat*. 2017;28(2):160–165.
58. Pannofino A. Recurrent oedema of the uvula in a patient with chronic spontaneous urticaria successfully treated with omalizumab. *J Dermatolog Treat*. 2018;29(Suppl 4):S8–S9.
59. Staubach P, Metz M, Chapman-Rothe N, et al. Omalizumab rapidly improves angioedema-related quality of life in adult patients with chronic spontaneous urticaria: x-ACT study data. *Allergy*. 2018;73(3):576–584.
60. Sussman GL, Hebert J, Simons FER. A 63-year-old man with chronic spontaneous urticaria. *Cmaj*. 2016;188(4):279–283.
61. Uysal P, Eller E, Mortz CG, Bindselev-Jensen C. An algorithm for treating chronic urticaria with omalizumab: dose interval should be individualized. *J Allergy Clin Immunol*. 2014;133(3):914–915.
62. Romano C, Sellitto A, De Fanis U, et al. Omalizumab for difficult-to-treat dermatological conditions: clinical and Immunological features from a retrospective real-life experience. *Clin Drug Investig*. 2015;35(3):159–168.
63. Magen E, Schlesinger M, Hadari I. Chronic urticaria can be triggered by eradication of *Helicobacter pylori*. *Helicobacter*. 2013;18(1):83–87.
64. Lee N, Lee JD, Lee HY, Kang DR, Ye YM. Epidemiology of Chronic Urticaria in Korea Using the Korean Health Insurance Database, 2010–2014. *Allergy Asthma Immunol Res*. 2017;9(5):438–445.
65. Lanigan SW, Adams SJ, Gilkes JJ, Robinson TW. Association between urticaria and hypothyroidism. *Lancet*. 1984;1(8392):1476.
66. Lanigan SW, Short P, Moul P. The association of chronic urticaria and thyroid autoimmunity. *Clin Exp Dermatol*. 1987;12(5):335–338.
67. Leznoff A, Josse RG, Denburg J, Dolovich J. Association of chronic urticaria and angioedema with thyroid autoimmunity. *Arch Dermatol*. 1983;119(8):636–640.
68. Goldsobel AB, Rohr AS, Siegel SC, et al. Efficacy of doxepin in the treatment of chronic idiopathic urticaria. *J Allergy Clin Immunol*. 1986;78(5 Pt 1):867–873.
69. Amoroso A, Garzia P, Pasquarelli C, Sportelli G, Afeltra A. Hashimoto's thyroiditis associated with urticaria and angio-oedema: disappearance of cutaneous and mucosal manifestations after thyroidectomy. *J Clin Pathol*. 1997;50(3):254–256.
70. Cebeci F, Tanrikut A, Topcu E, Onsun N, Kurtulmus N, Uras AR. Association between chronic urticaria and thyroid autoimmunity. *Eur J Dermatol*. 2006;16(4):402–405.
71. Feibelmann TC, Gonçalves FT, Daud MS, Jorge Ade S, Mantese SA, Jorge PT. Avaliação da associação entre doença auto-imune de tireóide e urticária crônica idiopática [Assessment of association between autoimmune thyroid disease and chronic urticaria]. *Arq Bras Endocrinol Metabol*. 2007;51(7):1077–1083.
72. Mozena JD, Tiñana A, Negri J, Steinke JW, Borish L. Lack of a role for cross-reacting anti-thyroid antibodies in chronic idiopathic urticaria. *J Invest Dermatol*. 2010;130(7):1860–1865.
73. Sugiyama A, Nishie H, Takeuchi S, Yoshinari M, Furue M. Hashimoto's disease is a frequent comorbidity and an exacerbating factor of chronic spontaneous urticaria. *Allergol Immunopathol*. 2015;43(3):249–253.
74. Chung BY, Um JY, Kang SY, Kim HO, Park CW. Natural History of Chronic Urticaria in Korea. *Ann Dermatol*. 2020;32(1):38–46.
75. Lefèvre AC, Deleuran M, Vestergaard C. A long term case series study of the effect of omalizumab on chronic spontaneous urticaria. *Ann Dermatol*. 2013;25(2):242–245.
76. Ivyanskiy I, Sand C, Thomsen SF. Omalizumab for chronic urticaria: a case series and overview of the literature. *Case Rep Dermatol*. 2012;4(1):19–26.
77. O'Donnell BF, Francis DM, Swana GT, Seed PT, Kobza black A, Greaves MW. Thyroid autoimmunity in chronic urticaria. *Br J Dermatol*. 2005;153(2):331–335.
78. Asero R, Lorini M, Tedeschi A. Association of chronic urticaria with thyroid autoimmunity and Raynaud phenomenon with anticentromere antibodies. *J Allergy Clin Immunol*. 2003;111(5):1129–1130.
79. Zhang Y, Morita E, Matsuo H, Ueda D, Dekio S. Urticarial erythema associated with IgA myeloma. *J Dermatol*. 2004;31(8):661–665.
80. Staubach P, Vonend A, Burow G, Metz M, Magerl M, Maurer M. Patients with chronic urticaria exhibit increased rates of sensitisation to *Candida albicans*, but not to common moulds. *Mycoses*. 2009;52(4):334–338.
81. Armengot-Carbo M, Velasco-Pastor M, Rodrigo-Nicolas B, Pont-Sanjuan V, Quecedo-Estebanez E, Gimeno-Carpio E. Omalizumab in chronic urticaria: a retrospective series of 15 cases. *Dermatol Ther*. 2013;26(3):257–259.
82. Zimmer S, Peveling-Oberhag A, Weber A, Gilfert T, Rady-Pizarro U, Staubach P. Unique coexistence of cold and solar urticaria and its efficient treatment. *Br J Dermatol*. 2016;174(5):1150–1152.
83. Sagi L, Solomon M, Baum S, Lyakhovitsky A, Trau H, Barzilai A. Evidence for methotrexate as a useful treatment for steroid-dependent chronic urticaria. *Acta Derm Venereol*. 2011;91(3):303–306.
84. Hu HH, Ying KJ, Wu XH, Chai Y. Urticaria as the initial presentation of early stage bronchioloalveolar carcinoma: a case report. *Chin Med J*. 2012;125(11):2065–2066.
85. Baroni A, Faccenda F, Russo T, Piccolo V. Figurate paraneoplastic urticaria and prostate cancer. *Ann Dermatol*. 2012;24(3):366–367.
86. Asero R, Cugno M, Tedeschi A. Activation of blood coagulation in plasma from chronic urticaria patients with negative autologous plasma skin test. *J Eur Acad Dermatol Venereol*. 2011;25(2):201–205.

87. Vaida GA, Goldman MA, Bloch KJ. Testing for hepatitis B virus in patients with chronic urticaria and angioedema. *J Allergy Clin Immunol.* 1983;72(2):193–198.
88. Rumbly JS, Katz JL, Schocket AL. Resolution of chronic urticaria in patients with thyroid autoimmunity. *J Allergy Clin Immunol.* 1995;96(6 Pt 1):901–905.
89. Manganoni AM, Tucci G, Venturini M, Farisoglio C, Baronchelli C, Calzavara Pinton PG. Chronic urticaria associated with thyroid carcinoma: report of 4 cases. *J Investig Allergol Clin Immunol.* 2007;17(3):192–195.
90. Martina E, Damiani G, Grieco T, Foti C, Pigatto PDM, Offidani A. It is never too late to treat chronic spontaneous urticaria with omalizumab: real-life data from a multicenter observational study focusing on elderly patients. *Dermatol Ther.* 2021;34(2):e14841.
91. Kasperska-Zajac A, Jarzab J, Żerdzińska A, Bąk K, Grzanka A. Effective treatment of different phenotypes of chronic urticaria with omalizumab: case reports and review of literature. *Int J Immunopathol Pharmacol.* 2016;29(2):320–328.
92. Zubrinich CM, Puy RM, O’Hehir RE, Hew M. Strongyloides infection as a reversible cause of chronic urticaria. *J Asthma Allergy.* 2019;12:67–69.
93. Napolitano M, Patruno C. Chronic urticaria can be caused by cancer and resolves with its cure. *Allergy.* 2018;73(8):1750–1751.
94. McGirt LY, Vasagar K, Gober LM, Saini SS, Beck LA. Successful treatment of recalcitrant chronic idiopathic urticaria with sulfasalazine. *Arch Dermatol.* 2006;142(10):1337–1342.
95. Anderson MH, Wray BB, Hooks VH 3rd. Urticaria in a 68-year-old man. *Ann Allergy.* 1991;66(3):207–211.
96. Aldasouqi S, Satoh P, Cardona Z, Alrasheed T, McLeod M, Mohan M. Chronic Autoimmune Urticaria and Cognitive Impairment as Unusual Presenting Symptoms of Primary Hyperparathyroidism. *Endocr Pract.* 2018;24(Suppl 1):S134.
97. Urbach E. Endogenous Allergy. *Arch Dermatol Syphilol.* 1942;45(4):697–722.
98. Fricke J, Ávila G, Keller T, et al. Prevalence of chronic urticaria in children and adults across the globe: systematic review with meta-analysis. *Allergy.* 2020;75(2):423–432.
99. Cassano N, Colombo D, Bellia G, Zagni E, Vena GA. Gender-related differences in chronic urticaria. *G Ital Dermatol Venereol.* 2016;151(5):544–552.
100. Ghazanfar MN, Kibsgaard L, Thomsen SF, Vestergaard C. Risk of comorbidities in patients diagnosed with chronic urticaria: a nationwide registry-study. *World Allergy Organ J.* 2020;13(1):100097. doi:10.1016/j.waojou.2019.100097
101. Deza G, Brasileiro A, Bertolin-Colilla M, Curto-Barredo L, Pujol RM, Giménez-Arnau AM. Acquired cold urticaria: clinical features, particular phenotypes, and disease course in a tertiary care center cohort. *J Am Acad Dermatol.* 2016;75(5):918–924. doi:10.1016/j.jaad.2016.06.017
102. Horton BT. Hypersensitiveness to cold: with local and systemic manifestations of a histamine-like character: its amenability to treatment. *J Am Med Assoc.* 1936;107(16):1263–1269. doi:10.1001/jama.1936.02770420001001
103. Jain SV, Mullins RJ. Cold urticaria: a 20-year follow-up study. *J Eur Acad Dermatol Venereol.* 2016;30(12):2066–2071. doi:10.1111/jdv.13841
104. Kulthanan K, Tuchinda P, Chularojanamontri L, Kiratiwongwan R. Cold Urticaria: clinical Features and Natural Course in a Tropical Country. *Allergy Asthma Immunol Res.* 2019;11(4):538–547. doi:10.4168/aa.2019.11.4.538
105. Mathelier-Fusade P. Clinical predictive factors of severity in cold urticaria. *Arch Dermatol.* 1998;134(1):106–107. doi:10.1001/archderm.134.1.106
106. Neittaanmäki H. Cold urticaria. Clinical findings in 220 patients. *J Am Acad Dermatol.* 1985;13(4):636–644. doi:10.1016/S0190-9622(85)70208-3
107. Sánchez-Borges M, Ansotegui IJ, Baiardini I, et al. The challenges of chronic urticaria part 1: epidemiology, immunopathogenesis, comorbidities, quality of life, and management. *World Allergy Organ J.* 2021;14(6):100533. doi:10.1016/j.waojou.2021.100533
108. Ferrer M. Epidemiology, healthcare, resources, use and clinical features of different types of urticaria. *Alergológica 2005. J Investig Allergol Clin Immunol.* 2009;19(Suppl 2):S21–S26.
109. Kulthanan K, Jiamton S, Thumpimukvatana N, Pinkaew S. Chronic idiopathic urticaria: prevalence and clinical course. *J Dermatol.* 2007;34(5):294–301. doi:10.1111/j.1346-8138.2007.00276.x
110. Small P, Barrett D, Biskin N, Champlin E. Chronic urticaria and angioedema. *Clin Allergy.* 1982;12(2):131–136. doi:10.1111/j.1365-2222.1982.tb01631.x
111. Zhong H, Song Z, Chen W, et al. Chronic urticaria in Chinese population: a hospital-based multicenter epidemiological study. *Allergy.* 2014;69(3):359–364. doi:10.1111/all.12338
112. Dressler C, Werner RN, Eisert L, Zuberbier T, Nast A, Maurer M. Chronic inducible urticaria: a systematic review of treatment options. *J Allergy Clin Immunol.* 2018;141(5):1726–1734. doi:10.1016/j.jaci.2018.01.031
113. Chang H-W, Cheng H-M, Yen H-R, et al. Association between chronic idiopathic urticaria and hypertension: a population-based retrospective cohort study. *Ann Allergy Asthma Immunol.* 2016;116(6):554–558. doi:10.1016/j.anai.2016.04.001
114. Shalom G, Magen E, Babaev M, et al. Chronic urticaria and the metabolic syndrome: a cross-sectional community-based study of 11 261 patients. *J Eur Acad Dermatol Venereol.* 2018;32(2):276–281. doi:10.1111/jdv.14548
115. Chung S-D, Wang K-H, Tsai M-C, Lin H-C, Chen C-H, Taniyama Y. Hyperlipidemia is associated with chronic urticaria: a population-based study. *PLoS One.* 2016;11(3):e0150304. doi:10.1371/journal.pone.0150304
116. Ye YM, Jin HJ, Hwang EK, et al. Co-existence of chronic urticaria and metabolic syndrome: clinical implications. *Acta Derm Venereol.* 2013;93(2):156–160. doi:10.2340/00015555-1443
117. Suastika K, Dwipayana P, Ratna Saraswati IM, et al. Relationship between age and metabolic disorders in the population of Bali. *Journal of Clinical Gerontology and Geriatrics.* 2011;2(2):47–52. doi:10.1016/j.jcgg.2011.03.001
118. Zbiciak-Nylec M, Wcislo-Dziadecka D, Kasprzyk M, et al. Overweight and obesity may play a role in the pathogenesis of chronic spontaneous urticaria. *Clin Exp Dermatol.* 2018;43(5):525–528. doi:10.1111/ced.13368
119. Kolkhir P, Pogorelov D, Olisova O, Maurer M. Comorbidity and pathogenic links of chronic spontaneous urticaria and systemic lupus erythematosus - A systematic review. *Clin Exp Allergy.* 2016;46(2):275–287. doi:10.1111/cea.12673
120. Verneuil L, Leconte C, Ballet JJ, et al. Association between chronic urticaria and thyroid autoimmunity: a prospective study involving 99 patients. *Dermatology.* 2004;208(2):98–103. doi:10.1159/000076480

121. Pan X-F, Gu J-Q, Shan Z-Y. The prevalence of thyroid autoimmunity in patients with urticaria: a systematic review and meta-analysis. *Endocrine*. 2015;48(3):804–810. doi:10.1007/s12020-014-0367-y
122. Kasumagic-Halilovic E, Beslic N, Ovcina-Kurtovic N. Thyroid Autoimmunity in Patients with Chronic Urticaria. *Med Arch*. 2017;71(1):29–31. doi:10.5455/medarch.2017.71.29-31
123. Kolkhir P, Borzova E, Grattan C, Asero R, Pogorelov D, Maurer M. Autoimmune comorbidity in chronic spontaneous urticaria: a systematic review. *Autoimmun Rev*. 2017;16(12):1196–1208. doi:10.1016/j.autrev.2017.10.003
124. Ramos-Casals M, García-Carrasco M, Brito MP, López-Soto A, Font J. Autoimmunity and geriatrics: clinical significance of autoimmune manifestations in the elderly. *Lupus*. 2003;12(5):341–355. doi:10.1191/0961203303lu383ed
125. White MC, Holman DM, Goodman RA, Richardson LC. Cancer risk among older adults: time for cancer prevention to go silver. *Gerontologist*. 2019;59(Suppl 1):S1–S6.
126. Larenas-Linnemann D, Saini SS, Azamar-Jácome AA, Jensen-Jarolim E, Maurer M. Very rarely chronic urticaria can be caused by cancer and if so, resolves with its cure. *Allergy*. 2018;73(9):1925–1926.
127. Staubach P, Onnen K, Vonend A, et al. Autologous whole blood injections to patients with chronic urticaria and a positive autologous serum skin test: a placebo-controlled trial. *Dermatology*. 2006;212(2):150–159.
128. Yeh JW, Yang HS, Yang CC. Dermatological diseases associated with Hepatitis B virus infection. *Dermatol Sin*. 2020;38(3):142–150.
129. Kolkhir P, Pereverzhina N, Olisova O, Maurer M. Comorbidity of viral hepatitis and chronic spontaneous urticaria: a systematic review. *Allergy*. 2018;73(10):1946–1953.
130. Caproni M, Volpi W, Giomi B, et al. Chronic idiopathic and chronic autoimmune urticaria: clinical and immunopathological features of 68 subjects. *Acta Derm Venereol*. 2004;84(4):288–290.
131. Sabroe RA, Seed PT, Francis DM, Barr RM, Black AK, Greaves MW. Chronic idiopathic urticaria: comparison of the clinical features of patients with and without anti-IgE autoantibodies. *J Am Acad Dermatol*. 1999;40(3):443–450.
132. Metz M, Giménez-Arnau A, Borzova E, Grattan CE, Magerl M, Maurer M. Frequency and clinical implications of skin autoreactivity to serum versus plasma in patients with chronic urticaria. *J Allergy Clin Immunol*. 2009;123(3):705–706.
133. Kolkhir P, Balakirski G, Merk HF, Olisova O, Maurer M. Chronic spontaneous urticaria and internal parasites—a systematic review. *Allergy*. 2016;71(3):308–322.
134. Vázquez-Nava F, Martínez-Burnes J. Prevalence and factors associated to chronic urticaria. Analysis of the allergic rhinitis and symptoms related to asthma as factors associated to chronic urticaria in a urban area of northeastern of Mexico. *Alergología e inmunología clínica*. 2004;19:16–24.
135. Zazzali JL, Broder MS, Chang E, Chiu MW, Hogan DJ. Cost, utilization, and patterns of medication use associated with chronic idiopathic urticaria. *Ann Allergy Asthma Immunol*. 2012;108(2):98–102.
136. Zuberbier T, Balke M, Worm M, Edenharter G, Maurer M. Epidemiology of urticaria: a representative cross-sectional population survey. *Clin Exp Dermatol*. 2010;35(8):869–873.
137. Broder MS, Raimundo K, Antonova E, Chang E. Resource use and costs in an insured population of patients with chronic idiopathic/spontaneous urticaria. *Am J Clin Dermatol*. 2015;16(4):313–321.
138. Balp MM. The Burden of Chronic Urticaria from Brazilian Patients' Perspective. *Dermatol Ther*. 2017;7(4):535–545.
139. Balp MM, Vietri J, Tian H, Isherwood G. The Impact of Chronic Urticaria from the Patient's Perspective: a Survey in Five European Countries. *Patient*. 2015;8(6):551–558.
140. Vietri J, Turner SJ, Tian H, Isherwood G, Balp MM, Gabriel S. Effect of chronic urticaria on US patients: analysis of the National Health and Wellness Survey. *Ann Allergy Asthma Immunol*. 2015;115(4):306–311.
141. Sibbald RG, Cheema AS, Lozinski A, Tarlo S. Chronic urticaria. Evaluation of the role of physical, immunologic, and other contributory factors. *Int J Dermatol*. 1991;30(6):381–386.
142. Giménez-Arnau AM, Ferrer M, Peter H-J, Maurer M, Pujol RM. Urticaria crónica: estudio etiológico prospectivo e importancia del síndrome autoinmune. *Actas Dermo-Sifiliográficas*. 2004;95(9):560–566.
143. Kozel MM, Mekkes JR, Bossuyt PM, Bos JD. Natural course of physical and chronic urticaria and angioedema in 220 patients. *J Am Acad Dermatol*. 2001;45(3):387–391.
144. van der Valk PG, Moret G, Kiemeny LA. The natural history of chronic urticaria and angioedema in patients visiting a tertiary referral centre. *Br J Dermatol*. 2002;146(1):110–113.
145. Humphreys F, Hunter JA. The characteristics of urticaria in 390 patients. *Br J Dermatol*. 1998;138(4):635–638.
146. Schnyder B, Helbling A, Pichler WJ. Chronic idiopathic urticaria: natural course and association with Helicobacter pylori infection. *Int Arch Allergy Immunol*. 1999;119(1):60–63.
147. Vázquez Nava F, Almeida Arvizu VM, Sánchez Nuncio HR, Villanueva Carreto Mde L, Guidos Fogelbach GA. Prevalence and potential triggering factors of chronic urticaria and angioedema in an urban area of northeastern Mexico. *Rev Alerg Mex*. 2004;51(5):181–188.
148. Lindelöf B, Sigurgeirsson B, Wahlgren CF, Eklund G. Chronic urticaria and cancer: an epidemiological study of 1155 patients. *Br J Dermatol*. 1990;123(4):453–456.
149. Quaranta JH, Rohr AS, Rachelefsky GS, et al. The natural history and response to therapy of chronic urticaria and angioedema. *Ann Allergy*. 1989;62(5):421–424.
150. Nettis E, Dambra P, D'Oronzio L, et al. Reactivity to autologous serum skin test and clinical features in chronic idiopathic urticaria. *Clin Exp Dermatol*. 2002;27(1):29–31.
151. Asero R. Sex differences in the pathogenesis of chronic urticaria. *J Allergy Clin Immunol*. 2003;111(2):425–426.
152. Kim A. Association of chronic urticaria with Helicobacter Pylori infection in Erbil: a case-control study. *Zanco J Med Sci*. 2016;20:1376–1384.
153. Confino-Cohen R, Chodick G, Shalev V, Leshno M, Kimhi O, Goldberg A. Chronic urticaria and autoimmunity: associations found in a large population study. *J Allergy Clin Immunol*. 2012;129(5):1307–1313.
154. Ozkan M, Ofiaz SB, Kocaman N, et al. Psychiatric morbidity and quality of life in patients with chronic idiopathic urticaria. *Ann Allergy Asthma Immunol*. 2007;99(1):29–33.
155. Campos V, Yassumoto L, Filho O, Antunes R, Calamita Z. Chronic spontaneous urticaria: cutaneous reaction and laboratory aspects. *Jornal Brasileiro de Patologia e Medicina Laboratorial*. 2016;52:84–90.

156. Guttman-Yassky E, Bergman R, Maor C, Mamorsky M, Pollack S, Shahar E. The autologous serum skin test in a cohort of chronic idiopathic urticaria patients compared to respiratory allergy patients and healthy individuals. *J Eur Acad Dermatol Venereol*. 2007;21(1):35–39.
157. Najib U, Bajwa ZH, Ostro MG, Sheikh J. A retrospective review of clinical presentation, thyroid autoimmunity, laboratory characteristics, and therapies used in patients with chronic idiopathic urticaria. *Ann Allergy Asthma Immunol*. 2009;103(6):496–501.
158. Viswanathan RK, Biagtan MJ, Mathur SK. The role of autoimmune testing in chronic idiopathic urticaria. *Ann Allergy Asthma Immunol*. 2012;108(5):337–341.
159. Ertas R, Hawro T, Altrichter S, et al. Antinuclear antibodies are common and linked to poor response to omalizumab treatment in patients with CSU. *Allergy*. 2020;75(2):468–470.
160. Chanprapaph K, Iamsung W, Wattanakrai P, Vachiramon V. Thyroid Autoimmunity and Autoimmunity in Chronic Spontaneous Urticaria Linked to Disease Severity, Therapeutic Response, and Time to Remission in Patients with Chronic Spontaneous Urticaria. *Biomed Res Int*. 2018;2018:9856843.
161. Kim JH, Oh TS, Lee SG, Kim IH. Prognostic significance of thyroid autoantibodies in urticaria. *Korean J Dermatol*. 2011;49(10):872–876.
162. Lee KR, Lee EG, Lee HJ, Yoon MS. Assessment of treatment efficacy and sebosuppressive effect of fractional radiofrequency microneedle on acne vulgaris. *Lasers Surg Med*. 2013;45(10):639–647.
163. Kayastha AK. Chronic Idiopathic Urticaria and its association with antithyroglobulin antibody. *Postgrad Med J NAMS*. 2011;11(2):24–27.
164. Sánchez-Borges M, Asero R, Ansotegui IJ, et al. Diagnosis and treatment of urticaria and angioedema: a worldwide perspective. *World Allergy Organ J*. 2012;5(11):125–147.
165. Tarbox JA, Gutta RC, Radojicic C, Lang DM. Utility of routine laboratory testing in management of chronic urticaria/angioedema. *Ann Allergy Asthma Immunol*. 2011;107(3):239–243.
166. Jiamton S, Swad-Ampiraks P, Kulthanan K, Suthipinittharm P. Urticaria and angioedema in Siriraj medical students. *J Med Assoc Thai*. 2003;86(1):74–81.
167. Champion RH, Roberts SO, Carpenter RG, Roger JH. Urticaria and angio-oedema. A review of 554 patients. *Br J Dermatol*. 1969;81(8):588–597.
168. Toubi E, Kessel A, Avshovich N, et al. Clinical and laboratory parameters in predicting chronic urticaria duration: a prospective study of 139 patients. *Allergy*. 2004;59(8):869–873.
169. Prostý C, Gabrielli S, Le M, et al. Prevalence, Management, and Anaphylaxis Risk of Cold Urticaria: a Systematic Review and Meta-Analysis. *J Allergy Clin Immunol Pract*. 2022;10(2):586–596.e584.
170. Magen E, Waitman DA, Dickstein Y, Davidovich V, Kahan NR. Clinical-laboratory characteristics of ANA-positive chronic idiopathic urticaria. *Allergy Asthma Proc*. 2015;36(2):138–144.
171. Zauli D, Deleonardi G, Foderaro S, et al. Thyroid autoimmunity in chronic urticaria. *Allergy Asthma Proc*. 2001;22(2):93–95.
172. Amin P, Levin L, Holmes SJ, Picard J, Bernstein JA. Investigation of patient-specific characteristics associated with treatment outcomes for chronic urticaria. *J Allergy Clin Immunol Pract*. 2015;3(3):400–407.
173. Missaka RF, Penatti HC, Silveiras MR, Nogueira CR, Mazeto GM. Autoimmune thyroid disease as a risk factor for angioedema in patients with chronic idiopathic urticaria: a case-control study. *Sao Paulo Med J*. 2012;130(5):294–298.
174. Rujitharanawong C, Tuchinda P, Chularojanamontri L, Chanchaemsri N, Kulthanan K. Cholinergic Urticaria: clinical Presentation and Natural History in a Tropical Country. *Biomed Res Int*. 2020;2020:7301652.
175. Vollono L, Piccolo A, Lanna C, et al. Omalizumab for chronic spontaneous urticaria in “complex” patients: data from real-life clinical practice. *Drug Des Devel Ther*. 2019;13:3181–3186.
176. Chiu HY, Muo CH, Sung FC. Associations of chronic urticaria with atopic and autoimmune comorbidities: a nationwide population-based study. *Int J Dermatol*. 2018;57(7):822–829.
177. Cascone N, Nee TL, Boeckman JE, Petrov AA, Fajt ML. The Impact of Allergic Disease in Adults with Chronic Idiopathic Urticaria. *J Allergy Clin Immunol*. 2019;143(2 suppl):AB75.
178. Miller DA, Freeman GL, Akers WA. Chronic urticaria: a clinical study of fifty patients. *Am J Med*. 1968;44(1):68–86.
179. Lee HC, Hong JB, Chu CY. Chronic idiopathic urticaria in Taiwan: a clinical study of demographics, aggravating factors, laboratory findings, serum autoreactivity and treatment response. *J Formos Med Assoc*. 2011;110(3):175–182.
180. Gallo C, Vighi G, Schroeder J, et al. Chronic urticaria atopic dermatitis and celiac disease. *Am J Gastroenterol*. 1992;87(11):1684.
181. Aitella E, De Bartolomeis F, Savoia A, Fabiani M, Romano M, Astarita C. The overlap syndrome of urticaria and gastroesophageal reflux disease. *PLoS One*. 2018;13(11):e0207602.
182. Doong JC, Chichester K, Oliver ET, Schwartz LB, Saini SS. Chronic Idiopathic Urticaria: systemic Complaints and Their Relationship with Disease and Immune Measures. *J Allergy Clin Immunol Pract*. 2017;5(5):1314–1318.
183. Fernandez Romero DS, Malbran A. Chronic urticaria with alterations of the thyroid function and thyroid peroxidase antibodies. *Medicina*. 2005;65(3):231–234.
184. Aamir IS, Tauheed S, Majid F, Atif A. Frequency of autoimmune thyroid disease in chronic urticaria. *J Coll Physicians Surg Pak*. 2010;20(3):158–161.
185. Staubach P, Dechene M, Metz M, et al. High prevalence of mental disorders and emotional distress in patients with chronic spontaneous urticaria. *Acta Derm Venereol*. 2011;91(5):557–561.
186. Uguz F, Engin B, Yilmaz E. Axis I and Axis II diagnoses in patients with chronic idiopathic urticaria. *J Psychosom Res*. 2008;64(2):225–229.
187. Staubach P, Eckhardt-Henn A, Dechene M, et al. Quality of life in patients with chronic urticaria is differentially impaired and determined by psychiatric comorbidity. *Br J Dermatol*. 2006;154(2):294–298.
188. Barbosa F, Freitas J, Barbosa A. Chronic idiopathic urticaria and anxiety symptoms. *J Health Psychol*. 2011;16(7):1038–1047.
189. Najmosadat A, Mahboobeh R, Shadi P, Shadi G. Psychological status in patients with chronic urticaria. *Med J Islam Repub Iran*. 2011;25(4):200–204.
190. Pulimood S, Rajagopalan B, Rajagopalan M, Jacob M, John JK. Psychiatric morbidity among dermatology inpatients. *Natl Med J India*. 1996;9(5):208–210.
191. Calikusu C, Yücel B, Polat A, Baykal C. The relation of psychogenic excoriation with psychiatric disorders: a comparative study. *Compr Psychiatry*. 2003;44(3):256–261.

192. Lindelöf B, Wahlgren CF. Chronic urticaria associated with internal malignancy. *Int J Dermatol*. 1990;29(5):384.
193. Breathnach SM, Allen R, Ward AM, Greaves MW. Symptomatic dermatographism: natural history, clinical features laboratory investigations and response to therapy. *Clin Exp Dermatol*. 1983;8(5):463–476.
194. Magerl M, Altrichter S, Borzova E, et al. The definition, diagnostic testing, and management of chronic inducible urticarias - The EAACI/GA (2) LEN/EDF/UNEV consensus recommendations 2016 update and revision. *Allergy*. 2016;71(6):780–802.
195. Kontou-Fili K, Borici-Mazi R, Kapp A, Matjevic LJ, Mitchel FB. Physical urticaria: classification and diagnostic guidelines. An EAACI position paper. *Allergy*. 1997;52(5):504–513.
196. Calamita Z, Pelá calamita AB. Chronic spontaneous urticaria: epidemiological characteristics focusing on the histocompatibility profile and presence of antibodies. *Inflamm Allergy Drug Targets*. 2013;12(1):8–11.
197. Viswanathan RK, Biagtan MJ, Mathur SK. Autoimmune profiling in chronic idiopathic urticaria – is there utility or futility? *J Allergy Clin Immunol*. 2012;129(2suppl):AB224.
198. Kim DH, Sung NH, Lee AY. Effect of Levothyroxine Treatment on Clinical Symptoms in Hypothyroid Patients with Chronic Urticaria and Thyroid Autoimmunity. *Ann Dermatol*. 2016;28(2):199–204.
199. Kessel A, Helou W, Bamberger E, et al. Elevated serum total IgE—a potential marker for severe chronic urticaria. *Int Arch Allergy Immunol*. 2010;153(3):288–293.
200. Stutes SA, Cho CB, Altrich M, Ardoin SP, Ogbogu PU. Auto-antibodies in Chronic Idiopathic Urticaria (CIU) and Non-urticarial Systemic Autoimmune Disorders. *J Allergy Clin Immunol*. 2012;129(2 suppl):AB224.
201. Krupa Shankar DS, Ramnane M, Rajouria EA. Etiological approach to chronic urticaria. *Indian J Dermatol*. 2010;55(1):33–38.
202. Abd El-Azim M, Abd El-Azim S. Chronic autoimmune urticaria: frequency and association with immunological markers. *J Investig Allergol Clin Immunol*. 2011;21(7):546–550.
203. Sajedi V, Movahedi M, Aghamohammadi A, et al. Comparison between sensitivity of autologous skin serum test and autologous plasma skin test in patients with Chronic Idiopathic Urticaria for detection of antibody against IgE or IgE receptor (FcεRIα). *Iran J Allergy Asthma Immunol*. 2011;10(2):111–117.
204. George M, Balachandran C, Prabhu S. Chronic idiopathic urticaria: comparison of clinical features with positive autologous serum skin test. *Indian J Dermatol Venereol Leprol*. 2008;74(2):105–108.
205. Godse KV. Autologous serum skin test in chronic idiopathic urticaria. *Indian J Dermatol Venereol Leprol*. 2004;70(5):283–284.
206. Kulthanan K, Jiamton S, Gorvanich T, Pinkaew S. Autologous serum skin test in chronic idiopathic urticaria: prevalence, correlation and clinical implications. *Asian Pac J Allergy Immunol*. 2006;24(4):201–206.
207. Lunge SB, Borkar M, Pande S. Correlation of serum antithyroid microsomal antibody and autologous serum skin test in patients with chronic idiopathic urticaria. *Indian Dermatol Online J*. 2015;6(4):248–252.
208. Marasoğlu Çelen O, Kutlubay Z, Aydemir EH. Usefulness of the autologous serum test for the diagnosis of chronic idiopathic urticaria. *Ann Dermatol*. 2014;26(5):592–597.
209. Curto-Barredo L, Yelamos J, Gimeno R, Mojal S, Pujol RM, Giménez-Arnau A. Basophil Activation Test identifies the patients with Chronic Spontaneous Urticaria suffering the most active disease. *Immun Inflamm Dis*. 2016;4(4):441–445.
210. Magen E, Zueva E, Mishal J, Schlesinger M. The clinical and laboratory characteristics of acute spontaneous urticaria and its progression to chronic spontaneous urticaria. *Allergy Asthma Proc*. 2016;37(5):394–399.
211. Rojo-Gutiérrez MI, Flores-Ruvalcaba CN, Mellado-ábrego J, Castillo-Narváez G, Ramírez-Rojas DP. Usefulness of studies looking for autoimmunity in patients with spontaneous chronic urticaria. *Rev Alerg Mex*. 2015;62(3):175–181.
212. Turktas I, Gokcora N, Demirsoy S, Cakir N, Onal E. The association of chronic urticaria and angioedema with autoimmune thyroiditis. *Int J Dermatol*. 1997;36(3):187–190.
213. Díaz-Angulo S, López-Hoyos M, Muñoz cacho P, et al. Prevalence of thyroid autoimmunity in Spanish patients with chronic idiopathic urticaria: a case-control study involving 343 subjects. *J Eur Acad Dermatol Venereol*. 2016;30(4):692–693.
214. Palma-Carlos AG, Palma-Carlos ML. Chronic urticaria and thyroid auto-immunity. *Eur Ann Allergy Clin Immunol*. 2005;37(4):143–146.
215. Chomiciene A, Jurgauskiene L, Blaziene A. Chronic urticaria and thyroid autoimmunity markers. *Cent Eur J Med*. 2012;7(6):736–741.
216. Alcaraz Calderón L, Escárcega Barbosa D, Castrejón Vázquez MI, et al. Presence of anti-Helicobacter pylori, antithyroid, and high-affinity IgE receptor antibodies in patients with chronic urticaria. *Rev Alerg Mex*. 2003;50(3):96–102.
217. Czarnecka-Operacz M, Sadowska-Przytocka A, Jenerowicz D, Szeliga A, Adamski Z, Łacka K. Thyroid function and thyroid autoantibodies in patients with chronic spontaneous urticaria. *Postepy Dermatol Alergol*. 2017;34(6):566–572.
218. Leznoff A, Sussman GL. Syndrome of idiopathic chronic urticaria and angioedema with thyroid autoimmunity: a study of 90 patients. *J Allergy Clin Immunol*. 1989;84(1):66–71.
219. Collet E, Petit JM, Lacroix M, Bensa AF, Morvan C, Lambert D. Chronic urticaria and autoimmune thyroid diseases. *Ann Dermatol Venereol*. 1995;122(6–7):413–416.
220. Ryhal B, DeMera RS, Shoenfeld Y, Peter JB, Gershwin ME. Are autoantibodies present in patients with subacute and chronic urticaria? *J Investig Allergol Clin Immunol*. 2001;11(1):16–20.
221. Kikuchi Y, Fann T, Kaplan AP. Antithyroid antibodies in chronic urticaria and angioedema. *J Allergy Clin Immunol*. 2003;112(1):218.
222. Atta AM, Rodrigues MZ, Sousa CP, Medeiros Júnior M, Sousa-Atta ML. Autoantibody production in chronic idiopathic urticaria is not associated with Helicobacter pylori infection. *Braz J Med Biol Res*. 2004;37(1):13–17.
223. Caproni M, Gioni B, Volpi W, et al. Chronic idiopathic urticaria: infiltrating cells and related cytokines in autologous serum-induced wheals. *Clin Immunol*. 2005;114(3):284–292.
224. Fusari A, Colangelo C, Bonifazi F, Antonicelli L. The autologous serum skin test in the follow-up of patients with chronic urticaria. *Allergy*. 2005;60(2):256–258.
225. Gangemi S, Saitta S, Lombardo G, Patafi M, Benvenega S. Serum thyroid autoantibodies in patients with idiopathic either acute or chronic urticaria. *J Endocrinol Invest*. 2009;32(2):107–110.
226. Ye YM, Park JW, Kim SH, et al. Prognostic Factors for Chronic Spontaneous Urticaria: a 6-Month Prospective Observational Study. *Allergy Asthma Immunol Res*. 2016;8(2):115–123.

227. Lee SY, Song WJ, Jung JW, et al. Thyroid autoantibodies and the prognosis of chronic idiopathic urticaria. *Allergy Asthma Respir Dis*. 2013;1(2):151–156.
228. Dionigi PC, Menezes MC, Forte WC. A prospective ten-year follow-up of patients with chronic urticaria. *Allergol Immunopathol*. 2016;44(4):286–291.
229. Oguz Topal I, Kocaturk E, Gungor S, Durmuscan M, Sucu V, Yildirmak S. Does replacement of vitamin D reduce the symptom scores and improve quality of life in patients with chronic urticaria? *J Dermatolog Treat*. 2016;27(2):163–166.
230. Okba AM, Sheha DS, Moustafa AS, El-Sherbeny AA, Mohamed NA, Aglan MF. Association between thyroid autoimmunity and chronic urticaria in patients versus healthy controls. *Egypt J Obes Diabetes Endocrinol*. 2015;1(2):84.
231. Chaykivska Z, Antoszczyk G, Czarnobilska E. The elevated level of anti-thyroid antibodies aTPO in chronic spontaneous urticaria. *Przegl Lek*. 2015;72(12):736–738.
232. Shin YS, Suh DH, Yang EM, Ye YM, Park HS. Serum Specific IgE to Thyroid Peroxidase Activates Basophils in Aspirin Intolerant Urticaria. *J Korean Med Sci*. 2015;30(6):705–709.
233. Arshi S, Babaie D, Nabavi M, et al. Circulating level of CD4+ CD25+ FOXP3+ T cells in patients with chronic urticaria. *Int J Dermatol*. 2014;53(12):e561–566.
234. Boonpiyathad T, Pradubpongsa P, Sangasapaviriya A. Vitamin d supplements improve urticaria symptoms and quality of life in chronic spontaneous urticaria patients: a prospective case-control study. *Dermatoendocrinol*. 2014;6:125. doi:10.4161/derm.29727
235. Irani C, Jammal M, Asmar G, Hajj H, Halaby G. Chronic urticaria and autoimmune thyroiditis. *J Med Liban*. 2012;60(2):88–90.
236. Concha LB, Chang CC, Szema AM, Dattwyler RJ, Carlson HE. IgE antithyroid antibodies in patients with Hashimoto's disease and chronic urticaria. *Allergy Asthma Proc*. 2004;25(5):293–296.
237. Al-Balbeesi AO. Significance of antithyroid antibodies and other auto-antibodies in Saudi patients with chronic urticaria. Possible parameters in predicting chronic over three years disease. *J Dermatol Dermatol Surg*. 2011;15(2):47–51.
238. Buss YA, Garrelfs UC, Sticherling M. Chronic urticaria—which clinical parameters are pathogenetically relevant? A retrospective investigation of 339 patients. *J Dtsch Dermatol Ges*. 2007;5(1):22–29.
239. Staubach P, Metz M, Chapman-Rothe N, et al. Effect of omalizumab on angioedema in H1 -antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial. *Allergy*. 2016;71(8):1135–1144.
240. Kaplan AP, Spector SL, Meeves S, Liao Y, Varghese ST, Georges G. Once-daily fexofenadine treatment for chronic idiopathic urticaria: a multicenter, randomized, double-blind, placebo-controlled study. *Ann Allergy Asthma Immunol*. 2005;94(6):662–669.
241. Perez A, Woods A, Grattan CE. Methotrexate: a useful steroid-sparing agent in recalcitrant chronic urticaria. *Br J Dermatol*. 2010;162(1):191–194.
242. Sanada S, Tanaka T, Kameyoshi Y, Hide M. The effectiveness of montelukast for the treatment of anti-histamine-resistant chronic urticaria. *Arch Dermatol Res*. 2005;297(3):134–138.
243. Reisman RE, Livingston A. Late-onset allergic reactions, including serum sickness, after insect stings. *J Allergy Clin Immunol*. 1989;84(3):331–337.
244. Greene SL, Reed CE, Schroeter AL. Double-blind crossover study comparing doxepin with diphenhydramine for the treatment of chronic urticaria. *J Am Acad Dermatol*. 1985;12(4):669–675.

Publish your work in this journal

The Journal of Asthma and Allergy is an international, peer-reviewed open-access journal publishing original research, reports, editorials and commentaries on the following topics: Asthma; Pulmonary physiology; Asthma related clinical health; Clinical immunology and the immunological basis of disease; Pharmacological interventions and new therapies. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/journal-of-asthma-and-allergy-journal>